Composition and mini-tablets for treating achondroplasia
Patent Information
- Application Number
- JP2023536825
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-18
- Filing Date
- 2021-12-17
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There are no approved therapeutic interventions for skeletal dysplasias such as achondroplasia, and current treatments are either ineffective or painful, with no clear growth effects shown by recombinant human growth hormone and limb lengthening surgery having significant complications.
The use of infigratinib, an FGFR inhibitor, administered orally in specific doses to pediatric patients with skeletal dysplasias, to promote bone growth and improve anthropometric measures.
Infigratinib treatment leads to increased height velocity, proportional body growth, and normalization of body ratios, along with decreased weight and improved quality of life in pediatric patients with skeletal dysplasias.
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Patent Application No. 63 / 127,576, filed December 18, 2020, the entire contents of each of which are incorporated by reference as if each were a part of this specification. [Background technology]
[0002] Skeletal dysplasia may affect bone development, cartilage growth and neurological function. Certain skeletal dysplasias, including achondroplasia (ACH) and hypochondroplasia (HCH), are forms of dwarfism. Achondroplasia (ACH) is the most common non-fatal skeletal dysplasia, affecting 1 in 15,000 to 30,000 people (Horton WA, Hall JG, Hecht JT., Achondroplasia. Lancet, 2007, 370, 162-72; Waller DK, Correa A, Vo TM, Wang Y, Hobbs C, Langlois PH, et al. Am. J. Med. Genet. A., 2008, 146A(18), 2385-2389). Patients with ACH are short, with an average height of about 4 feet (~125 cm), and prone to significant comorbidities such as sleep apnea, chronic otitis media with conductive hearing loss, spinal stenosis, obesity, and foramen magnum stenosis, which in some cases require urgent surgical intervention. HCH is similar to ACH and is characterized by less pronounced physical signs, although patients with HCH may also be affected by larger neurological problems, including mild to moderate intellectual disability and learning disabilities.
[0003] ACH is characterized by defective endochondral ossification due to gain-of-function mutations in the fibroblast growth factor receptor (FGFR) 3 gene. These mutations, 99% of which are G380R mutations (Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, et al., Am. J. Hu. Genet., 56, 368-373, 1995), render the receptor constitutively active and disrupt chondrocyte proliferation and differentiation in the growth plate, thereby inhibiting linear bone growth (Unger S, Bonafe L, Gouze D., Curr. Osteoporos. Rep., 2017, 15, 53-60). The primary phenotype of ACH is disproportionate short stature with radiculopathy (shortening of the proximal limbs).
[0004] Approximately 80% of cases are due to de novo mutations (Ornitz DM, Legeai-Mallet L., Dev. Dyn., 2017, 246, 291-309). Diagnosis is usually made at birth, but may be suspected on prenatal ultrasound.
[0005] In North America, Europe, or Australia, there are no approved therapeutic interventions for ACH or HCH, and no widely accepted consensus regarding treatment (Unger). Current treatment options are nontargeted, ineffective, or painful interventions aimed at preventing or treating the complications of ACH (FDA Background Document. Joint Meeting of the Pediatrics Advisory Committee and the Endocrine and Metabolic Drugs Advisory Committee. May 11, 2018. Available at: https: / / www.fda.gov / downloads / AdvisoryCommittees / ; Unger).
[0006] No clear growth benefit has been shown after treatment with recombinant human growth hormone (r-hGH). Although an increase in growth velocity has been observed (height increased from -5.0 to -4.0 standard deviations over 5 years), no clear benefit has been established for long-term treatment (Miccoli M, Bertelloni S, Massart F., Horm. Res. Paediatr., 2016, 86, 27-34). In general, it is not a recommended treatment option for ACH (Horton; FDA).
[0007] Limb lengthening can provide 15 to 30 cm of additional height (~20% increased bone segment length), but the procedure is painful, often requires revision surgery, and has a high complication rate (Horton). In addition, growth plate growth rates may be hindered by these procedures, and the cosmetic effect of longer legs and shorter arms may not be suitable for some patients (FDA). Currently, clinicians considering limb lengthening generally require a psychological evaluation and require the child to be old enough to consent to the procedure (Wright MJ, Irving MD., Arch. Dis. Child., 2012, 97(2), 129-134).
[0008] Thus, there remains an unmet need to develop new therapeutic strategies to treat children with skeletal dysplasias such as achondroplasia and hypochondroplasia. Summary of the Invention [Problem to be solved by the invention]
[0009] The present disclosure provides methods of treating skeletal dysplasia using an FGFR inhibitor, namely infigratinib.
[0010] In one aspect, provided herein is a method of treating a skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof, the method generally comprising orally administering to the pediatric patient from about 0.01 mg / kg to about 0.51 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof daily.
[0011] In certain embodiments, the method comprises administering about 0.01 mg / kg to about 0.3 mg / kg of infigratinib or a pharmaceutically acceptable salt thereof to the pediatric patient. In certain embodiments, the method comprises administering about 0.01 mg / kg to about 0.15 mg / kg of infigratinib or a pharmaceutically acceptable salt thereof to the pediatric patient. In certain embodiments, the method comprises administering about 0.015 mg / kg to about 0.13 mg / kg of infigratinib or a pharmaceutically acceptable salt thereof to the pediatric patient. In certain embodiments, the method comprises administering about 0.016 mg / kg, about 0.032 mg / kg, about 0.064 mg / kg, about 0.128 mg / kg, about 0.256 mg / kg, or about 0.51 mg / kg of infigratinib or a pharmaceutically acceptable salt thereof to the pediatric patient.
[0012] In another aspect, provided herein is a method of treating a pediatric patient suffering from a skeletal dysplasia, such as achondroplasia or hypochondroplasia, the method generally comprising orally administering to the patient daily about 0.1 mg to about 8 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
[0013] In certain embodiments, the methods comprise administering to a pediatric patient about 1 mg to about 7 mg of infigratinib, or a pharma- ceutically acceptable salt thereof.
[0014] In certain embodiments, the pediatric patient has an FGFR3 mutation. In certain embodiments, the FGFR3 mutation is a G380R mutation.
[0015] In certain embodiments, infigratinib or a pharma- ceutically acceptable salt thereof is administered as mini-tablets, each having about 0.1 mg or about 1 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
[0016] In certain embodiments, infigratinib is present in the mini-tablets as infigratinib monophosphate. In certain embodiments, infigratinib monophosphate is present as an anhydrous crystalline form. In certain embodiments, the anhydrous crystalline form of infigratinib monophosphate is characterized by an XRPD peak at 15.0°±0.2° (2θ).
[0017] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase in height velocity relative to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase in absolute height velocity.
[0018] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase over baseline in an anthropometric measurement selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute increase in an anthropometric measurement selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof.
[0019] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a decrease in body weight compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute decrease in body weight.
[0020] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a proportional increase in head circumference compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute proportional increase in head circumference.
[0021] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a normalization of body ratio measurements compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute normalization of body ratio measurements. In certain embodiments, the body ratio measurements are selected from the group consisting of upper to lower body body part ratio, upper arm to forearm ratio, upper leg to lower leg length ratio, arm span to height ratio, head circumference to height ratio, and combinations thereof.
[0022] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an increase over baseline in a biomarker of bone turnover selected from the group consisting of type X collagen degradation fragments, collagen X markers, and combinations thereof.
[0023] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an increase in exercise capacity compared to baseline.
[0024] In certain embodiments, after administration of a daily dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits a reduction in the number of episodes of otitis media compared to baseline.
[0025] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits a reduction in the number and / or severity of sleep apnea episodes compared to baseline.
[0026] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an increase in quality of life, where the quality of life is assessed using the Pediatric Quality of Life Inventory.
[0027] In certain embodiments, the pediatric patient is 12 years old or younger. In certain embodiments, the pediatric patient is 3 to 11 years old. In certain embodiments, the pediatric patient is under 8 years old. In certain embodiments, the pediatric patient is 8 years old or older.
[0028] In another embodiment, provided herein are mini-tablets for oral administration of about 1 mg of infigratinib, the mini-tablets generally comprising an amount of infigratinib monophosphate to administer about 1 mg of infigratinib, and pharma- ceutically acceptable excipients.
[0029] In another aspect, provided herein are mini-tablets for oral administration of about 0.1 mg of infigratinib, the mini-tablets generally consisting of infigratinib monophosphate in an amount to administer about 0.1 mg of infigratinib, and pharma- ceutically acceptable excipients.
[0030] In certain embodiments, the pharma- ceutically acceptable excipient is selected from the group consisting of mannitol, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium stearate, croscarmellose sodium, and combinations thereof.
[0031] In another aspect, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 1% w / w to about 20% w / w of infigratinib monophosphate and about 30% w / w to about 95% w / w of a filler.
[0032] In certain embodiments, the filler is selected from the group consisting of microcrystalline cellulose, lactose, mannitol, and combinations thereof, hi certain embodiments, the filler comprises microcrystalline cellulose and mannitol.
[0033] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w of a binder, hi certain embodiments, the binder is selected from the group consisting of sugar, gelatin, natural gums, sorbitol, maltodextrin, alginates, alginate derivatives, polyvinylpyrrolidone, cellulose, cellulose derivatives, and combinations thereof.
[0034] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w of a disintegrant, hi certain embodiments, the disintegrant is selected from the group consisting of starch, starch derivatives, clay, crosslinked cellulose, crosslinked cellulose derivatives, crosslinked polyvinylpyrrolidone, and combinations thereof.
[0035] In another aspect, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 1% w / w to about 20% w / w of infigratinib monophosphate, about 30% w / w to about 60% w / w of mannitol and about 30% w / w to about 45% w / w of microcrystalline cellulose.
[0036] In certain embodiments, the mini-tablets comprise about 10% w / w to about 20% w / w of infigratinib monophosphate. In certain embodiments, the mini-tablets comprise about 1% w / w to about 5% w / w of infigratinib monophosphate.
[0037] In certain embodiments, the mini-tablets comprise about 30% w / w to about 45% w / w mannitol. In certain embodiments, the mini-tablets comprise about 45% w / w to about 60% w / w mannitol. In certain embodiments, the mini-tablets comprise about 35% w / w to about 40% w / w microcrystalline cellulose.
[0038] In another aspect, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 10% w / w to about 20% w / w of infigratinib monophosphate, about 30% w / w to about 45% w / w of mannitol and about 30% w / w to about 40% w / w of microcrystalline cellulose.
[0039] In another aspect, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 1% w / w to about 5% w / w of infigratinib monophosphate, about 45% w / w to about 60% w / w of mannitol and about 30% w / w to about 40% w / w of microcrystalline cellulose.
[0040] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w cross-linked polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 2% w / w to about 6% w / w croscarmellose sodium.
[0041] In another embodiment, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 1.2 mg of infigratinib monophosphate, about 3 mg to about 4 mg of mannitol, and about 2 mg to about 4.4 mg of microcrystalline cellulose.
[0042] In certain embodiments, the mini-tablets further comprise from about 0.6 mg to about 0.8 mg of polyvinylpyrrolidone, hi certain embodiments, the mini-tablets further comprise from about 0.5 mg to about 0.7 mg of cross-linked polyvinylpyrrolidone.
[0043] In another embodiment, provided herein are mini-tablets for oral administration, the mini-tablets comprising about 0.12 mg of infigratinib monophosphate, about 3 mg to about 4 mg of mannitol, and about 2 mg to about 3 mg of microcrystalline cellulose.
[0044] In certain embodiments, the mini-tablets further comprise about 0.4 mg to about 0.6 mg of polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 0.3 mg to about 0.5 mg of cross-linked polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 0.2 mg to about 0.4 mg of croscarmellose sodium. [Means for solving the problem]
[0045] As generally described herein, the present disclosure provides a method of treating skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof. The method generally includes administering to the pediatric patient an effective amount of infigratinib (e.g., 0.01 milligrams per kilogram (mg / kg) to about 0.51 mg / kg). Additionally, mini-tablets for administering an effective amount of infigratinib to the pediatric patient are provided, e.g., the mini-tablets include infigratinib monophosphate and one or more pharma- ceutically acceptable excipients (e.g., fillers, binders, disintegrants, lubricants).
[0046] definition To facilitate the understanding of this invention, a number of terms and phrases are defined below.
[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. Abbreviations used herein have their conventional meanings in the chemical and biological arts. Chemical structures and formulas described herein are constructed according to the standard rules of chemical valency known in the chemical arts.
[0048] Throughout this specification, where compositions and kits are described as having, comprising or consisting of certain components, or where processes and methods are described as having, comprising or consisting of certain steps, it is further contemplated that there are compositions and kits according to the invention which consist or consist essentially of the recited components, and that there are processes and methods according to the invention which consist or consist essentially of the recited process steps.
[0049] In this application, when an element or component is said to be included in and / or selected from a list of recited elements or components, it is to be understood that the element or component can be any one of the recited elements or components, or the element or component can be selected from the group consisting of two or more of the recited elements or components.
[0050] Furthermore, it should be understood that elements and / or features of the compositions or methods described herein can be combined in various ways without departing from the spirit and scope of the invention, whether expressly or implicitly stated herein. For example, when a particular compound is mentioned, that compound can be used in various embodiments of the compositions of the invention and / or in the methods of the invention, unless otherwise understood from the context. In other words, within this application, although the embodiments have been described and depicted in a manner that allows the application to be written and drawn in a clear and concise manner, it is intended and understood that the embodiments can be combined or separated in various ways without departing from the present teachings and invention(s). For example, it will be understood that all features described and depicted herein are applicable to all aspects of the invention described and depicted herein.
[0051] The articles "a" and "an" are used in this disclosure, unless the context is inappropriate, to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or one or more than one element.
[0052] In this disclosure, the term "and / or" is used to mean either "and" or "or," unless otherwise indicated.
[0053] The phrase "at least one" should be understood to include each of the listed objects following the phrase individually, and various combinations of two or more of the listed objects, unless otherwise understood from context and usage. Also, the phrase "and / or" in the context of more than two recited objects should be understood to have the same meaning, unless otherwise understood from context.
[0054] Use of the terms "include," "includes," "including," "have," "has," "having," "contain," "contains," or "containing," including grammatical equivalents thereof, is to be generally understood as open-ended and open-ended, e.g., not excluding additional, unrepeated elements or steps, unless otherwise stated or understood from the context.
[0055] When the term "about" is used before a quantitative value, the invention also includes the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term "about" refers to a ±10% variation from the nominal value, unless otherwise indicated or inferred from the context.
[0056] At various places in the present specification, variables or parameters are disclosed in groups or ranges. Each individual subcombination of the members of such groups or ranges is specifically intended to be included herein. For example, an integer in the range of 0 to 40 is specifically intended to individually disclose 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40, and an integer in the range of 1 to 20 is specifically intended to individually disclose 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
[0057] The use of any examples or exemplary language herein, such as "such as" or "including," is intended merely to better describe the invention and does not limit the scope of the invention unless claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0058] As a general matter, compositions specifying percentages are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, the variable's prior definition is controlling.
[0059] As used herein, a "pharmaceutical composition" or "pharmaceutical formulation" refers to a combination of an active agent and an excipient, inactive agent, or active agent that makes the composition or formulation particularly suitable for in vivo or ex vivo diagnostic or therapeutic uses.
[0060] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or State government or a corresponding agency in a country other than the United States, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
[0061] As used herein, "pharmaceutically acceptable salt" refers to any salt of acidic or basic groups that may be present in the compounds of the invention (e.g., infigratinib), which salt is compatible with pharmaceutical administration.
[0062] As known to those skilled in the art, the "salts" of compounds can be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, ethanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid and benzenesulfonic acid. Other acids, such as oxalic acid, are not themselves pharmaceutically acceptable, but can be used in the preparation of salts useful as intermediates to obtain the compounds described herein and their pharmaceutically acceptable acid addition salts.
[0063] Examples of bases include alkali metal (e.g., sodium and potassium) hydroxides, alkaline earth metal (e.g., magnesium and calcium) hydroxides, ammonia, and bases of the formula NW4 + (Wherein, W is C 1~4 alkyl), and the like.
[0064] Examples of salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, etc. Other examples of salts include Na + , K + , Ca 2+ , NH4 + , NW4 + (Where, W is C 1~4 Examples of suitable cations include the anions of the compounds of the present invention combined with suitable cations such as an alkyl group.
[0065] For therapeutic use, the salts of the compounds of the invention are pharma-ceutically acceptable. However, salts of acids and bases that are non-pharma-ceutically acceptable may also find use, for example, in the preparation or purification of a pharma-ceutically acceptable compound.
[0066] As used herein, "pharmaceutical acceptable excipient" refers to a substance that aids in the administration and / or absorption of an active agent by a subject and can be included in the compositions of the present invention without causing significant toxicological side effects to the patient. Non-limiting examples of pharmaceutical acceptable excipients include water, NaCl, normal saline such as phosphate buffered saline, emulsions (e.g., oil / water or water / oil emulsions), lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (such as Ringer's solution), alcohol, oils, gelatin, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidine, and colorings. Such preparations can be sterilized and, if desired, mixed with auxiliary agents that do not dramatically react with the compounds of the present invention, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for affecting osmotic pressure, buffers, colorings, and / or aromatics. For examples of excipients, see Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA (1975).
[0067] The term "AUC" refers to the area under the time / plasma concentration curve following administration of a pharmaceutical composition. AUC 0-infinity represents the area under the plasma concentration versus time curve from time 0 to infinity, AUC 0-t represents the area under the plasma concentration versus time curve from time 0 to time t. AUC values can be measured by methods known in the art.
[0068] "Subjects" to which administration is contemplated include humans (i.e., male or female of any age, e.g., a pediatric subject (e.g., infant, child, adolescent) or an adult subject (e.g., young adult, middle-aged adult, or elderly adult)) and / or non-human animals, e.g., mammals such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms "subject" and "patient" are used interchangeably herein.
[0069] "C max " refers to the maximum concentration of a therapeutic agent (e.g., infigratinib) in the blood (e.g., plasma) following administration of a pharmaceutical composition.
[0070] "t max " refers to the administration of a pharmaceutical composition containing a therapeutic agent (e.g., infigratinib) followed by C max This refers to the time (unit: hours) at which the above is achieved.
[0071] As used herein, "solid dosage form" means a pharmaceutical dosage in solid form, including, for example, tablets, capsules, granules, powders, sachets, reconstitutable powders, dry powder inhalants and chewables.
[0072] As used herein, "administering" refers to oral administration, administration as a suppository, topical contact, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intraarticular administration, intrathecal administration, intracranial administration, intranasal administration, or subcutaneous administration, or implantation of a sustained release device, such as a mini-osmotic pump, into a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of administration include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. "Co-administration" refers to administration of a composition described herein simultaneously with, immediately prior to, or immediately following administration of one or more additional therapies (e.g., anti-cancer agents, chemotherapeutic agents, or agents for treating neurodegenerative diseases). Infigratinib or its pharmaceutically acceptable salts can be administered alone or co-administered (e.g., with other therapeutic agents) to a patient. Co-administration means that the compound is administered alone or in combination with one or more additional agents, such as one or more additional therapeutic agents, either simultaneously or sequentially. Thus, the formulation can be combined with other active substances, if desired (e.g., to reduce metabolic degradation).
[0073] The terms "disease," "disorder," and "condition" are used interchangeably herein.
[0074] As used herein, and unless otherwise specified, the terms "treat", "treating" and "treatment" contemplate actions occurring while a subject is suffering from a specified disease, disorder or condition that reduce the severity of the disease, disorder or condition or slow or retard the progression of the disease, disorder or condition (e.g., "therapeutic treatment"). Treatment may refer to indicators of success in ameliorating a disease, disorder or condition, including objective or subjective parameters such as relief, remission, alleviation of symptoms, or making the disease, disorder or condition more tolerable to the patient, slowing the rate of degeneration or decline, making the end point of degeneration less debilitating, and / or improving the physical or mental well-being of the patient. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, a neuropsychiatric examination, and / or a psychiatric evaluation. Treatment can also be preemptive in nature; i.e., it can include prevention of the disease, disorder or condition, prevention of the onset of one or more symptoms of the disease, disorder or condition, and / or prevention of the spread of the disease, disorder or condition. Prevention of a disease, disorder, or condition can include complete protection from the disease and / or prevention of disease progression (e.g., progression to a later stage of the disease, disorder, or condition). For example, prevention of a disease does not mean a complete blockage of all effects associated with the disease at any level, but instead can mean preventing the manifestations of the disease, disorder, or condition to a clinically significant or detectable level.
[0075] In general, an "effective amount" of a compound refers to an amount sufficient to induce a desired biological response, e.g., to treat a skeletal dysplasia such as achondroplasia or hypochondroplasia. As will be appreciated by one of skill in the art, the effective amount of a compound of the present disclosure may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, and the age, weight, health of the subject.
[0076] Infigratinib Infigratinib, as represented by formula (I), is a selective, ATP-competitive pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, also known as 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{6-[4-(4-ethyl-1-piperazin-1-yl)phenylamino]-pyrimidinyl-4-yl}-1-methylurea. Infigratinib selectively inhibits the kinase activity of FGFR1, FGFR2 and FGFR3. TIFF2024500404000001.tif33161
[0077] Methods for chemically synthesizing infigratinib (including Example 1 provided herein), several crystalline and amorphous forms of infigratinib (including the anhydrous crystalline monophosphate salt described herein) and methods for preparing said forms (including Example 2 provided herein) are described in U.S. Pat. No. 9,067,896, which is incorporated herein by reference in its entirety.
[0078] In one aspect, provided herein is infigratinib, or a pharma- ceutically acceptable salt thereof, for the treatment of a skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof.
[0079] In certain embodiments, provided herein is a pharmaceutically acceptable salt of infigratinib for the treatment of skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof. In some embodiments, the pharmaceutically acceptable salt of infigratinib is a monophosphate. The monophosphate salt of infigratinib can be referred to as BGJ398, infigratinib phosphate, and infigratinib monophosphate.
[0080] In some embodiments, the monophosphate salt of infigratinib is anhydrous crystalline monophosphate salt. In some embodiments, the anhydrous crystalline monophosphate salt has an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak in 2θ at about 15.0° or 15.0°±0.2°. In some embodiments, the X-ray powder diffraction pattern of the anhydrous crystalline monophosphate salt further comprises one or more characteristic peaks in 2θ selected from peaks at about 13.7°±0.2°, about 16.8°±0.2°, about 21.3°±0.2° and about 22.4°±0.2°. In some embodiments, the X-ray powder diffraction pattern of the anhydrous crystalline monophosphate salt further comprises one or more characteristic peaks in 2θ selected from peaks at about 9.2°, about 9.6°, about 18.7°, about 20.0°, about 22.9° and about 27.2°. In some embodiments, the anhydrous crystalline monophosphate has an XRPD pattern that includes at least three characteristic peaks in terms of 2θ selected from peaks at about 13.7°, about 15°, about 16.8°, about 21.3°, and about 22.4°. In some embodiments, the X-ray powder diffraction pattern of the anhydrous crystalline monophosphate includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 characteristic peaks in terms of 2θ selected from peaks at about 9.2°, about 9.6°, about 13.7°, about 15°, about 16.8°, about 18.7°, about 20.0°, about 21.3°, about 22.4°, about 22.9°, and about 27.2°.
[0081] Pharmaceutical Compositions In one aspect, provided herein is a pharmaceutical composition comprising infigratinib or a pharma- ceutical acceptable salt thereof and a pharma- ceutical acceptable excipient for the treatment of skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof.
[0082] In various embodiments, provided herein is a pharmaceutical composition comprising infigratinib and a pharma- ceutical acceptable excipient for the treatment of skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof.
[0083] In various embodiments, provided herein is a pharmaceutical composition comprising a pharma- ceutical acceptable salt of infigratinib and a pharma- ceutical acceptable excipient for the treatment of skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof. In certain embodiments, the pharma- ceutical acceptable salt of infigratinib is infigratinib monophosphate.
[0084] In certain embodiments, the pharmaceutical composition is a mini-tablet. In certain embodiments, the mini-tablet is for oral administration.
[0085] In various embodiments, provided herein are mini-tablets for oral administration of infigratinib, comprising infigratinib monophosphate and a pharma- ceutically acceptable excipient. In certain embodiments, the mini-tablets orally administer about 0.1 milligrams (mg) of infigratinib. In certain embodiments, the mini-tablets orally administer about 1 mg of infigratinib.
[0086] In various embodiments, provided herein are mini-tablets for oral administration of about 0.1 mg of infigratinib, comprising infigratinib monophosphate and pharma- ceutically acceptable excipients.
[0087] In various embodiments, provided herein are mini-tablets for oral administration of about 1 mg of infigratinib, comprising infigratinib monophosphate and pharma- ceutically acceptable excipients.
[0088] In certain embodiments, the pharma- ceutically acceptable excipient is selected from the group consisting of mannitol, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium stearate, croscarmellose sodium, and combinations thereof.
[0089] In various embodiments, provided herein are mini-tablets for oral administration comprising about 1% w / w to about 20% w / w of infigratinib monophosphate and about 30% w / w to about 95% w / w of a filler.
[0090] In one embodiment, the mini-tablets comprise from about 1% w / w to about 20% w / w, from about 2% w / w to about 20% w / w, from about 3% w / w to about 20% w / w, from about 4% w / w to about 20% w / w, from about 5% w / w to about 20% w / w, from about 6% w / w to about 20% w / w, from about 7% w / w to about 20% w / w, from about 8% w / w to about 20% w / w, from about 9% w / w to about 20% w / w, from about 10% w / w to about 20% w / w, from about 11% w / w to about 20% w / w, from about 12% w / w to about 20% w / w, from about 13% w / w to about 20% w / w, from about 14% w / w to about 20% w / w, 15% w / w to about 20% w / w, about 16% w / w to about 20% w / w, about 17% w / w to about 20% w / w, about 18% w / w to about 20% w / w, about 19% w / w to about 20% w / w, about 1% w / w to about 19% w / w, about 1% w / w to about 18% w / w, about 1% w / w to about 17% w / w, about 1% w / w to about 16% w / w, about 1% w / w to about 15% w / w, about 1% w / w to about 14% w / w, about 1% w / w to about 13% w / w, about 1% w / w to about 12% w / w, about 1% w / w to about 11% w / w, about 1% w / w to about 10% w / w, about from about 9% w / w, from about 1% w / w to about 8% w / w, from about 1% w / w to about 7% w / w, from about 1% w / w to about 6% w / w, from about 1% w / w to about 5% w / w, from about 1% w / w to about 4% w / w, from about 1% w / w to about 3% w / w, from about 1% w / w to about 2% w / w, from about 2% w / w to about 19% w / w, from about 2% w / w to about 18% w / w, from about 2% w / w to about 17% w / w, from about 2% w / w to about 16% w / w, from about 2% w / w to about 15% w / w, from about 2% w / w to about 14% w / w, from about 2% w / w to about 13% w / w, from about 2% w / w to about 12% w / w, % w / w to about 11% w / w, about 2% w / w to about 10% w / w, about 2% w / w to about 9% w / w, about 2% w / w to about 8% w / w, about 2% w / w to about 7% w / w, about 2% w / w to about 6% w / w, about 2% w / w to about 5% w / w, about 2% w / w to about 4% w / w, about 2% w / w to about 3% w / w, about 3% w / w to about 19% w / w, about 3% w / w to about 18% w / w, about 3% w / w to about 17% w / w, about 3% w / w to about 16% w / w, about 3% w / w to about 15% w / w, about 3% w / w to about 14% w / w, about 3% w / w to about 13% w / w,from about 3% w / w to about 12% w / w, from about 3% w / w to about 11% w / w, from about 3% w / w to about 10% w / w, from about 3% w / w to about 9% w / w, from about 3% w / w to about 8% w / w, from about 3% w / w to about 7% w / w, from about 3% w / w to about 6% w / w, from about 3% w / w to about 5% w / w, from about 3% w / w to about 4% w / w, from about 4% w / w to about 19% w / w, from about 4% w / w to about 18% w / w, from about 4% w / w to about 17% w / w, from about 4% w / w to about 16% w / w, from about 4% w / w to about 15% w / w, from about 4% w / w to about 14% w / w, from about 4% w / w to about 13% w / w / w, from about 4% w / w to about 12% w / w, from about 4% w / w to about 11% w / w, from about 4% w / w to about 10% w / w, from about 4% w / w to about 9% w / w, from about 4% w / w to about 8% w / w, from about 4% w / w to about 7% w / w, from about 4% w / w to about 6% w / w, from about 4% w / w to about 5% w / w, from about 5% w / w to about 19% w / w, from about 5% w / w to about 18% w / w, from about 5% w / w to about 17% w / w, from about 5% w / w to about 16% w / w, from about 5% w / w to about 15% w / w, from about 5% w / w to about 14% w / w, from about 5% w / w to about 13% w / w, from about 5% w / w to about 12% w / w, about 5% w / w to about 11% w / w, about 5% w / w to about 10% w / w, about 5% w / w to about 9% w / w, about 5% w / w to about 8% w / w, about 5% w / w to about 7% w / w, about 5% w / w to about 6% w / w, about 6% w / w to about 19% w / w, about 6% w / w to about 18% w / w, about 6% w / w to about 17% w / w, about 6% w / w to about 16% w / w, about 6% w / w to about 15% w / w, about 6% w / w to about 14% w / w, about 6% w / w to about 13% w / w, about 6% w / w to about 12% w / w, about 6% w / w to about 11% w / w, about 6% w / w to about 15% w / w, about 6% w / w to about 15% w / w, about 6% w / w to about 16% w / w, about 6% w / w to about 15 ... / w to about 10% w / w, about 6% w / w to about 9% w / w, about 6% w / w to about 8% w / w, about 6% w / w to about 7% w / w, about 7% w / w to about 19% w / w, about 7% w / w to about 18% w / w, about 7% w / w to about 17% w / w, about 7% w / w to about 16% w / w, about 7% w / w to about 15% w / w, about 7% w / w to about 14% w / w, about 7% w / w to about 13% w / w, about 7% w / w to about 12% w / w, about 7% w / w to about 11% w / w, about 7% w / w to about 10% w / w, about 7% w / w to about 9% w / w, about 7% w / w to about 8% w / w,from about 8% w / w to about 19% w / w, from about 8% w / w to about 18% w / w, from about 8% w / w to about 17% w / w, from about 8% w / w to about 16% w / w, from about 8% w / w to about 15% w / w, from about 8% w / w to about 14% w / w, from about 8% w / w to about 13% w / w, from about 8% w / w to about 12% w / w, from about 8% w / w to about 11% w / w, from about 8% w / w to about 10% w / w, from about 8% w / w to about 9% w / w, from about 9% w / w to about 19% w / w, from about 9% w / w to about 18% w / w, from about 9% w / w to about 17% w / w, from about 9% w / w to about 16% w / w, from about 9% w / w to about 1 5% w / w, about 9% w / w to about 14% w / w, about 9% w / w to about 13% w / w, about 9% w / w to about 12% w / w, about 9% w / w to about 11% w / w, about 9% w / w to about 10% w / w, about 10% w / w to about 19% w / w, about 10% w / w to about 18% w / w, about 10% w / w to about 17% w / w, about 10% w / w to about 16% w / w, about 10% w / w to about 15% w / w, about 10% w / w to about 14% w / w, about 10% w / w to about 13% w / w, about 10% w / w to about 12% w / w, about 10% w / w to about 11% w / w, about 11% w / w to about 1 9% w / w, about 11% w / w to about 18% w / w, about 11% w / w to about 17% w / w, about 11% w / w to about 16% w / w, about 11% w / w to about 15% w / w, about 11% w / w to about 14% w / w, about 11% w / w to about 13% w / w, about 11% w / w to about 12% w / w, about 12% w / w to about 19% w / w, about 12% w / w to about 18% w / w, about 12% w / w to about 17% w / w, about 12% w / w to about 16% w / w, about 12% w / w to about 15% w / w, about 12% w / w to about 14% w / w, about 12% w / w to about 13% w / w, about 13% w / w / w to about 19% w / w, about 13% w / w to about 18% w / w, about 13% w / w to about 17% w / w, about 13% w / w to about 16% w / w, about 13% w / w to about 15% w / w, about 13% w / w to about 14% w / w, about 14% w / w to about 19% w / w, about 14% w / w to about 18% w / w, about 14% w / w to about 17% w / w, about 14% w / w to about 16% w / w, about 14% w / w to about 15% w / w, about 15% w / w to about 19% w / w, about 15% w / w to about 18% w / w, about 15% w / w to about 17% w / w, about 15% w / w to about 16% w / w,In a particular embodiment, the mini-tablets comprise about 1% w / w to about 5% w / w of infigratinib monophosphate. In a particular embodiment, the mini-tablets comprise about 10% w / w to about 20% w / w of infigratinib monophosphate.
[0091] In certain embodiments, the mini-tablets comprise about 1% w / w, about 2% w / w, about 3% w / w, about 4% w / w, about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, about 10% w / w, about 11% w / w, about 12% w / w, about 13% w / w, about 14% w / w, about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w or about 20% w / w of infigratinib monophosphate.
[0092] In certain embodiments, the mini-tablets are from about 30% w / w to about 95% w / w, from about 35% w / w to about 95% w / w, from about 40% w / w to about 95% w / w, from about 45% w / w to about 95% w / w, from about 50% w / w to about 95% w / w, from about 55% w / w to about 95% w / w, from about 60% w / w to about 95% w / w, from about 65% w / w to about 95% w / w, from about 70% w / w to about 95% w / w, from about 75% w / w to about 95% w / w, from about 80% w / w to about 95% w / w, from about 85% w / w to about 95% w / w, from about 90% w / w to about 95% w / w, from about 30% w / w from about 90% w / w, from about 30% w / w to about 85% w / w, from about 30% w / w to about 80% w / w, from about 30% w / w to about 75% w / w, from about 30% w / w to about 70% w / w, from about 30% w / w to about 65% w / w, from about 30% w / w to about 60% w / w, from about 30% w / w to about 55% w / w, from about 30% w / w to about 50% w / w, from about 30% w / w to about 45% w / w, from about 30% w / w to about 40% w / w, from about 30% w / w to about 35% w / w, from about 35% w / w to about 90% w / w, from about 35% w / w to about 85% w / w, from about 35% w / w to about 80% w / w , about 35% w / w to about 75% w / w, about 35% w / w to about 70% w / w, about 35% w / w to about 65% w / w, about 35% w / w to about 60% w / w, about 35% w / w to about 55% w / w, about 35% w / w to about 50% w / w, about 35% w / w to about 45% w / w, about 35% w / w to about 40% w / w, about 40% w / w to about 90% w / w, about 40% w / w to about 85% w / w, about 40% w / w to about 80% w / w, about 40% w / w to about 75% w / w, about 40% w / w to about 70% w / w, about 40% w / w to about 65% w / w, about 40 ...45% w / w to about 40% w / w, about 40% w / w to about 90% w / w, about 40% from about 60% w / w, from about 40% w / w to about 55% w / w, from about 40% w / w to about 50% w / w, from about 40% w / w to about 45% w / w, from about 45% w / w to about 90% w / w, from about 45% w / w to about 85% w / w, from about 45% w / w to about 80% w / w, from about 45% w / w to about 75% w / w, from about 45% w / w to about 70% w / w, from about 45% w / w to about 65% w / w, from about 45% w / w to about 60% w / w, from about 45% w / w to about 55% w / w, from about 45% w / w to about 50% w / w, from about 50% w / w to about 90% w / w, from about 50% w / w to about 85% w / w,about 50% w / w to about 80% w / w, about 50% w / w to about 75% w / w, about 50% w / w to about 70% w / w, about 50% w / w to about 65% w / w, about 50% w / w to about 60% w / w, about 50% w / w to about 55% w / w, about 55% w / w to about 90% w / w, about 55% w / w to about 85% w / w, about 55% w / w to about 80% w / w, about 55% w / w to about 75% w / w, about 55% w / w to about 70% w / w, about 55% w / w to about 65% w / w, about 55% w / w to about 60% w / w, about 60% w / w to about 90% w / w, about 60% w / w to about 85% w / w, about 60% w / w to about 80% w / w, about 60% w / w to about 75% w / w, about 60% w / w to about 70% w / w, about 60% w / w to about 65% w / w, about 65% w / w to about 90% w / w, about 65% w / w to about 85% w / w, about 65% w / w to about 80% w / w, about 65% w / w to about 75% w / w, about 65% w / w to about 70% w / w, about 70% w / w to about 90% w / w, about 70% w / w to about 85% w / w / w, about 70% w / w to about 80% w / w, about 70% w / w to about 75% w / w, about 75% w / w to about 90% w / w, about 75% w / w to about 85% w / w, about 75% w / w to about 80% w / w, about 80% w / w to about 90% w / w, about 80% w / w to about 85% w / w, or about 80% w / w to about 90% w / w of filler.
[0093] In certain embodiments, the mini-tablets comprise about 30% w / w, about 35% w / w, about 40% w / w, about 45% w / w, about 50% w / w, about 55% w / w, about 60% w / w, about 65% w / w, about 70% w / w, about 75% w / w, about 80% w / w, about 85% w / w, about 90% w / w or about 95% w / w of filler.
[0094] In certain embodiments, the filler comprises microcrystalline cellulose, lactose, mannitol, and combinations thereof.
[0095] In certain embodiments, the fillers include microcrystalline cellulose and mannitol.
[0096] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w, about 6% w / w to about 10% w / w, about 7% w / w to about 10% w / w, about 8% w / w to about 10% w / w, about 9% w / w to about 10% w / w, about 5% w / w to about 9% w / w, about 5% w / w to about 8% w / w, about 5% w / w to about 7% w / w, about 5% w / w to about 6% w / w, about 6% w / w to about 9% w / w, about 6% w / w to about 8% w / w, about 6% w / w to about 7% w / w, about 7% w / w to about 9% w / w, about 7% w / w to about 8% w / w, or about 8% w / w to about 9% w / w of a binder.
[0097] In certain embodiments, the mini-tablets further comprise about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w or about 10% w / w of a binder.
[0098] In certain embodiments, the binder is selected from the group consisting of sugars (e.g., glucose, sucrose), gelatin, natural gums (e.g., acacia, tragacanth), sorbitol, maltodextrin, alginates (e.g., sodium alginate), alginic acid derivatives, polyvinylpyrrolidone, cellulose (e.g., microcrystalline cellulose), cellulose derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose), and combinations thereof.
[0099] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w, about 6% w / w to about 10% w / w, about 7% w / w to about 10% w / w, about 8% w / w to about 10% w / w, about 9% w / w to about 10% w / w, about 5% w / w to about 9% w / w, about 5% w / w to about 8% w / w, about 5% w / w to about 7% w / w, about 5% w / w to about 6% w / w, about 6% w / w to about 9% w / w, about 6% w / w to about 8% w / w, about 6% w / w to about 7% w / w, about 7% w / w to about 9% w / w, about 7% w / w to about 8% w / w, or about 8% w / w to about 9% w / w of a disintegrant. In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w of a disintegrant.
[0100] In certain embodiments, the mini-tablets further comprise about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w or about 10% w / w of a disintegrant.
[0101] In certain embodiments, the disintegrant is selected from the group consisting of starches (e.g., potato, corn, and corn starch), starch derivatives (e.g., low substituted carboxymethyl starch and pregelatinized starch), clays (e.g., Veegum HV and bentonite), crosslinked cellulose, crosslinked cellulose derivatives (e.g., crosslinked sodium carboxymethylcellulose), crosslinked polyvinylpyrrolidone, and combinations thereof.
[0102] In various embodiments, provided herein are mini-tablets for oral administration comprising about 1% w / w to about 20% w / w of infigratinib monophosphate, about 30% w / w to about 60% w / w of mannitol, and about 30% w / w to about 45% w / w of microcrystalline cellulose.
[0103] In certain embodiments, the mini-tablets are from about 30% w / w to about 60% w / w, from about 35% w / w to about 60% w / w, from about 40% w / w to about 60% w / w, from about 45% w / w to about 60% w / w, from about 50% w / w to about 60% w / w, from about 55% w / w to about 60% w / w, from about 30% w / w to about 55% w / w, from about 30% w / w to about 50% w / w, from about 30% w / w to about 45% w / w, from about 30% w / w to about 40% w / w, from about 30% w / w to about 55% w / w, In certain embodiments, the mini-tablets comprise from about 30% w / w to about 45% w / w mannitol. In certain embodiments, the mini-tablets comprise from about 45% w / w to about 60% w / w mannitol.
[0104] In certain embodiments, the mini-tablets comprise about 30% w / w, about 35% w / w, about 40% w / w, about 45% w / w, about 50% w / w, about 55% w / w or about 60% w / w mannitol.
[0105] In certain embodiments, the mini-tablets comprise about 30% w / w to about 45% w / w, about 35% w / w to about 45% w / w, about 40% w / w to about 45% w / w, about 30% w / w to about 40% w / w, about 30% w / w to about 35% w / w, or about 35% w / w to about 40% w / w of microcrystalline cellulose. In certain embodiments, the mini-tablets comprise about 35% w / w to about 40% w / w of microcrystalline cellulose.
[0106] In various embodiments, provided herein are mini-tablets for oral administration comprising about 10% w / w to about 20% w / w of infigratinib monophosphate, about 30% w / w to about 45% w / w of mannitol, and about 30% w / w to about 40% w / w of microcrystalline cellulose.
[0107] In various embodiments, provided herein are mini-tablets for oral administration comprising about 1% w / w to about 5% w / w of infigratinib monophosphate, about 45% w / w to about 60% w / w of mannitol, and about 30% w / w to about 40% w / w of microcrystalline cellulose.
[0108] In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w, about 6% w / w to about 10% w / w, about 7% w / w to about 10% w / w, about 8% w / w to about 10% w / w, about 9% w / w to about 10% w / w, about 5% w / w to about 9% w / w, about 5% w / w to about 8% w / w, about 5% w / w to about 7% w / w, about 5% w / w to about 6% w / w, about 6% w / w to about 9% w / w, about 6% w / w to about 8% w / w, about 6% w / w to about 7% w / w, about 7% w / w to about 9% w / w, about 7% w / w to about 8% w / w, or about 8% w / w to about 9% w / w of polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w polyvinylpyrrolidone.
[0109] In certain embodiments, the mini-tablets further comprise about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w or about 10% w / w of polyvinylpyrrolidone.
[0110] In certain embodiments, the mini-tablets further comprise from about 5% w / w to about 10% w / w, from about 6% w / w to about 10% w / w, from about 7% w / w to about 10% w / w, from about 8% w / w to about 10% w / w, from about 9% w / w to about 10% w / w, from about 5% w / w to about 9% w / w, from about 5% w / w to about 8% w / w, from about 5% w / w to about 7% w / w, from about 5% w / w to about 6% w / w, from about 6% w / w to about 9% w / w, from about 6% w / w to about 8% w / w, from about 6% w / w to about 7% w / w, from about 7% w / w to about 9% w / w, from about 7% w / w to about 8% w / w, or from about 8% w / w to about 9% w / w of cross-linked polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise about 5% w / w to about 10% w / w of cross-linked polyvinylpyrrolidone.
[0111] In certain embodiments, the mini-tablets further comprise about 2% w / w to about 6% w / w, about 3% w / w to about 6% w / w, about 4% w / w to about 6% w / w, about 5% w / w to about 6% w / w, about 2% w / w to about 5% w / w, about 2% w / w to about 4% w / w, about 2% w / w to about 3% w / w, about 3% w / w to about 5% w / w, about 3% w / w to about 4% w / w, or about 4% w / w to about 5% w / w of croscarmellose sodium. In certain embodiments, the mini-tablets further comprise about 2% w / w to about 6% w / w of croscarmellose sodium.
[0112] In certain embodiments, the mini-tablets further comprise a lubricant. In certain embodiments, the mini-tablets further comprise about 0.25% w / w to about 1% w / w, about 0.5% w / w to about 1% w / w, about 0.75% w / w to about 1% w / w, about 0.25% w / w to about 0.75% w / w, about 0.25% w / w to about 0.5% w / w, or about 0.5% w / w to about 0.75% w / w of a lubricant. In certain embodiments, the mini-tablets further comprise about 0.5% w / w to about 0.75% w / w of a lubricant.
[0113] In certain embodiments, the mini-tablets further comprise about 0.25% w / w, about 0.3% w / w, about 0.35% w / w, about 0.4% w / w, about 0.45% w / w, about 0.5% w / w, about 0.55% w / w, about 0.6% w / w, about 0.65% w / w, about 0.7% w / w, about 0.75% w / w, about 0.8% w / w, about 0.85% w / w, about 0.9% w / w, about 0.95% w / w, or about 1% w / w of a lubricant. In certain embodiments, the mini-tablets further comprise about 0.5% w / w of a lubricant. In certain embodiments, the mini-tablets further comprise about 0.75% w / w of a lubricant. In certain embodiments, the mini-tablets further comprise about 1% w / w of a lubricant.
[0114] In certain embodiments, the lubricant is magnesium stearate.
[0115] In certain embodiments, the mini-tablets further comprise a colorant.
[0116] In various embodiments, provided herein are mini-tablets for oral administration comprising about 1.2 mg of infigratinib monophosphate, about 3 mg to about 4 mg of mannitol, and about 2 mg to about 4.4 mg of microcrystalline cellulose.
[0117] In various embodiments, provided herein are mini-tablets for oral administration comprising about 0.12 mg of infigratinib monophosphate, about 3 mg to about 4 mg of mannitol, and about 2 mg to about 3 mg of microcrystalline cellulose.
[0118] In certain embodiments, the mini-tablets contain about 3 mg to about 4 mg, about 3.2 mg to about 4 mg, about 3.4 mg to about 4 mg, about 3.6 mg to about 4 mg, about 3.8 mg to about 4 mg, about 3 mg to about 3.8 mg, about 3 mg to about 3.6 mg, about 3 mg to about 3.4 mg, about 3 mg to about 3.2 mg, about 3.2 mg to about 3.8 mg, about 3.2 mg to about 3.6 mg, about 3.2 mg to about 3.4 mg, about 3.4 mg to about 3.8 mg, about 3.4 mg to about 3.6 mg, or about 3.6 mg to about 3.8 mg of mannitol.
[0119] In certain embodiments, the mini-tablets contain about 3 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, about 3.5 mg, about 3.6 mg, about 3.7 mg, about 3.8 mg, about 3.9 mg or about 4 mg of mannitol.
[0120] In certain embodiments, the mini-tablets are from about 2 mg to about 4.4 mg, from about 2.2 mg to about 4.4 mg, from about 2.4 mg to about 4.4 mg, from about 2.6 mg to about 4.4 mg, from about 2.8 mg to about 4.4 mg, from about 3 mg to about 4.4 mg, from about 3.2 mg to about 4.4 mg, from about 3.4 mg to about 4.4 mg, from about 3.6 mg to about 4.4 mg, from about 3.8 mg to about 4.4 mg, from about 4 mg to about 4.4 mg, from about 4.2 mg to about 4.4 mg, from about 2 mg to about 4.2 mg, from about 2 mg to about 4 mg, from about 2 mg to about 3.8 mg, from about 2 mg to about 3.6 mg, from about 2 mg to about 4.4 mg, about 3.4mg, about 2mg to about 3.2mg, about 2mg to about 3mg, about 2mg to about 2.8mg, about 2mg to about 2.6mg, about 2mg to about 2.4mg, about 2mg to about 2.2mg, about 2.2mg to about 4.2mg, about 2.2mg to about 4mg, about 2.2mg to about 3.8mg, about 2.2mg to about 3.6mg, about 2.2mg to about 3.4mg, about 2.2mg to about 3.2mg, about 2.2mg to about 3mg, about 2.2mg to about 2.8mg, about 2.2mg to about 2.6mg, about 2.2mg to about 2.4mg, about 2.4mg to about 4.2mg, about 2.4mg g to about 4 mg, about 2.4 mg to about 3.8 mg, about 2.4 mg to about 3.6 mg, about 2.4 mg to about 3.4 mg, about 2.4 mg to about 3.2 mg, about 2.4 mg to about 3 mg, about 2.4 mg to about 2.8 mg, about 2.4 mg to about 2.6 mg, about 2.6 mg to about 4.2 mg, about 2.6 mg to about 4 mg, about 2.6 mg to about 3.8 mg, about 2.6 mg to about 3.6 mg, about 2.6 mg to about 3.4 mg, about 2.6 mg to about 3.2 mg, about 2.6 mg to about 3 mg, about 2.6 mg to about 2.8 mg, about 2.8 mg to about 4.2 mg, about 2.8 mg from about 4 mg, from about 2.8 mg to about 3.8 mg, from about 2.8 mg to about 3.6 mg, from about 2.8 mg to about 3.4 mg, from about 2.8 mg to about 3.2 mg, from about 2.8 mg to about 3.0 mg, from about 3 mg to about 4.2 mg, from about 3 mg to about 4 mg, from about 3 mg to about 3.8 mg, from about 3 mg to about 3.6 mg, from about 3 mg to about 3.4 mg, from about 3 mg to about 3.2 mg, from about 3.2 mg to about 4.2 mg, from about 3.2 mg to about 4 mg, from about 3.2 mg to about 3.8 mg, from about 3.2 mg to about 3.6 mg, from about 3.2 mg to about 3.4 mg, from about 3.4 mg to about 4.2 mg, from about 3.4 mg to about 4 mg, about 3.4 mg to about 3.8 mg, about 3.4 mg to about 3.6 mg, about 3.6 mg to about 4.2 mg, about 3.6 mg to about 4 mg, about 3.6 mg to about 3.8 mg, about 3.8 mg to about 4.2 mg, about 3.8 mg to about 4 mg, or about 4 mg to about 4.2 mg of crystalline cellulose.
[0121] In certain embodiments, the mini-tablets contain about 2 mg, about 2.2 mg, about 2.4 mg, about 2.6 mg, about 2.8 mg, about 3 mg, about 3.2 mg, about 3.4 mg, about 3.6 mg, about 3.8 mg, about 4 mg, about 4.2 mg or about 4.4 mg of microcrystalline cellulose.
[0122] In certain embodiments, the mini-tablets comprise from about 0.4 mg to about 0.6 mg, from about 0.45 mg to about 0.6 mg, from about 0.5 mg to about 0.6 mg, from about 0.55 mg to about 0.6 mg, from about 0.4 mg to about 0.55 mg, from about 0.4 mg to about 0.5 mg, from about 0.4 mg to about 0.45 mg, from about 0.45 mg to about 0.55 mg, from about 0.45 mg to about 0.5 mg, or from about 0.5 mg to about 0.55 mg of polyvinylpyrrolidone. In certain embodiments, the mini-tablets further comprise from about 0.4 mg to about 0.6 mg of polyvinylpyrrolidone.
[0123] In certain embodiments, the mini-tablets further comprise about 0.4 mg, about 0.42 mg, about 0.44 mg, about 0.46 mg, about 0.48 mg, about 0.5 mg, about 0.52 mg, about 0.54 mg, about 0.56 mg, about 0.58 mg, or about 0.6 mg of polyvinylpyrrolidone.
[0124] In certain embodiments, the mini-tablets further comprise about 0.3 mg to about 0.5 mg, about 0.35 mg to about 0.5 mg, about 0.4 mg to about 0.5 mg, about 0.45 mg to about 0.5 mg, about 0.3 mg to about 0.45 mg, about 0.3 mg to about 0.4 mg, about 0.3 mg to about 0.35 mg, about 0.35 mg to about 0.45 mg, about 0.35 mg to about 0.4 mg, or about 0.4 mg to about 0.45 mg. In certain embodiments, the mini-tablets further comprise about 0.3 mg to about 0.5 mg of cross-linked polyvinylpyrrolidone.
[0125] In certain embodiments, the mini-tablets further comprise about 0.3 mg, about 0.32 mg, about 0.34 mg, about 0.36 mg, about 0.38 mg, about 0.4 mg, about 0.42 mg, about 0.44 mg, about 0.46 mg, about 0.48 mg, or about 0.5 mg of cross-linked polyvinylpyrrolidone.
[0126] In certain embodiments, the mini-tablets further comprise about 0.2 mg to about 0.4 mg, about 0.25 mg to about 0.4 mg, about 0.3 mg to about 0.4 mg, about 0.35 mg to about 0.4 mg, about 0.2 mg to about 0.35 mg, about 0.2 mg to about 0.3 mg, about 0.2 mg to about 0.25 mg, about 0.25 mg to about 0.35 mg, about 0.25 mg to about 0.3 mg, or about 0.3 mg to about 0.35 mg of croscarmellose sodium. In certain embodiments, the mini-tablets further comprise about 0.2 mg to about 0.4 mg of croscarmellose sodium.
[0127] In certain embodiments, the mini-tablets further comprise about 0.2 mg, about 0.22 mg, about 0.24 mg, about 0.26 mg, about 0.28 mg, about 0.3 mg, about 0.32 mg, about 0.34 mg, about 0.36 mg, about 0.38 mg, or about 0.4 mg of croscarmellose sodium.
[0128] In certain embodiments, the mini-tablets are further comprised between about 0.03 mg to about 0.09 mg, about 0.04 mg to about 0.09 mg, about 0.05 mg to about 0.09 mg, about 0.06 mg to about 0.09 mg, about 0.07 mg to about 0.09 mg, about 0.08 mg to about 0.09 mg, about 0.03 mg to about 0.08 mg, about 0.03 mg to about 0.07 mg, about 0.03 mg to about 0.06 mg, about 0.03 mg to about 0.05 mg, about 0.03 ...8 mg, g to about 0.04 mg, about 0.04 mg to about 0.08 mg, about 0.04 mg to about 0.07 mg, about 0.04 mg to about 0.06 mg, about 0.04 mg to about 0.05 mg, about 0.05 mg to about 0.08 mg, about 0.05 mg to about 0.07 mg, about 0.05 mg to about 0.06 mg, about 0.06 mg to about 0.08 mg, about 0.06 mg to about 0.07 mg, or about 0.07 mg to about 0.08 mg of magnesium stearate.
[0129] In certain embodiments, the mini-tablets further comprise about 0.03 mg, about 0.035 mg, about 0.04 mg, about 0.045 mg, about 0.05 mg, about 0.055 mg, about 0.06 mg, about 0.065 mg, about 0.07 mg, about 0.075 mg, about 0.08 mg, about 0.085 mg, about 0.09 mg, about 0.095 mg, or about 0.1 mg of magnesium stearate. In certain embodiments, the mini-tablets further comprise about 0.035 mg of magnesium stearate. In certain embodiments, the mini-tablets further comprise about 0.055 mg of magnesium stearate. In certain embodiments, the mini-tablets further comprise about 0.07 mg of magnesium stearate. In certain embodiments, the mini-tablets further comprise about 0.085 mg of magnesium stearate.
[0130] In certain embodiments, infigratinib monophosphate exists as an anhydrous crystalline form. In certain embodiments, the anhydrous crystalline form of infigratinib monophosphate is characterized by an XRPD peak at 15.0°±0.2° (2θ).
[0131] Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to any type of animal. Modifications of pharmaceutical compositions suitable for administration to humans to make the compositions suitable for administration to a variety of animals are well understood, and an ordinarily skilled veterinary pharmacologist can design and / or perform such modifications with routine experimentation. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington: The Science and Practice of Pharmacy 21 st ed., Lippincott Williams & Wilkins, 2005.
[0132] Methods of Use and Treatment Skeletal dysplasias that affect bone development and other functions include, for example, achondroplasia or hypochondroplasia. Achondroplasia (ACH) is the most common non-lethal form of skeletal dysplasia and is characterized by defective endochondral ossification due to gain-of-function mutations in the fibroblast growth factor receptor (FGFR) 3 gene.
[0133] In one aspect, provided herein is a method of treating a skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof.
[0134] In various embodiments, provided herein is a method of treating a skeletal dysplasia, such as achondroplasia or hypochondroplasia, in a pediatric patient in need thereof, comprising orally administering to the pediatric patient about 0.01 mg / kg to about 0.51 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof daily.
[0135] In certain embodiments, the method comprises administering to the patient a dose of about 0.01 mg / kg to about 0.51 mg / kg, about 0.05 mg / kg to about 0.51 mg / kg, about 0.1 mg / kg to about 0.51 mg / kg, about 0.15 mg / kg to about 0.51 mg / kg, about 0.2 mg / kg to about 0.51 mg / kg, about 0.25 mg / kg to about 0.51 mg / kg, about 0.3 mg / kg to about 0.51 mg / kg, about 0.35 mg / kg to about 0.51 mg / kg, about 0.4 mg / kg to about 0.51 mg / kg, about 0.45 mg / kg to about 0.51 mg / kg, about 0.0 1 mg / kg to about 0.45 mg / kg, about 0.01 mg / kg to about 0.4 mg / kg, about 0.01 mg / kg to about 0.35 mg / kg, about 0.01 mg / kg to about 0.3 mg / kg, about 0.01 mg / kg to about 0.25 mg / kg, about 0.01 mg / kg to about 0.2 mg / kg, about 0.01 mg / kg to about 0.15 mg / kg, about 0.01 mg / kg to about 0.1 mg / kg, about 0.01 mg / kg to about 0.05 mg / kg, about 0.05 mg / kg to about 0.45 mg / kg, about 0.05 mg / kg to about 0.4 mg / kg, about 0.0 5mg / kg to about 0.35mg / kg, about 0.05mg / kg to about 0.3mg / kg, about 0.05mg / kg to about 0.25mg / kg, about 0.05mg / kg to about 0.2mg / kg, about 0.05mg / kg to about 0.15mg / kg, about 0.05mg / kg to about 0.1mg / kg, about 0.1mg / kg to about 0.45mg / kg, about 0.1mg / kg to about 0.4mg / kg, about 0.1mg / kg to about 0.35mg / kg, about 0.1mg / kg to about 0.3mg / kg, about 0.1mg / kg to about 0.25mg / kg, about 0.1mg / kg from about 0.2 mg / kg, from about 0.1 mg / kg to about 0.15 mg / kg, from about 0.15 mg / kg to about 0.45 mg / kg, from about 0.15 mg / kg to about 0.4 mg / kg, from about 0.15 mg / kg to about 0.35 mg / kg, from about 0.15 mg / kg to about 0.3 mg / kg, from about 0.15 mg / kg to about 0.25 mg / kg, from about 0.15 mg / kg to about 0.2 mg / kg, from about 0.2 mg / kg to about 0.45 mg / kg, from about 0.2 mg / kg to about 0.4 mg / kg, from about 0.2 mg / kg to about 0.35 mg / kg, from about 0.2 mg / kg to about 0.The present invention relates to a method for administering infigratinib or a pharmacologic agent to a pediatric patient, the method comprising administering to the pediatric patient about 3 mg / kg, about 0.2 mg / kg to about 0.25 mg / kg, about 0.25 mg / kg to about 0.45 mg / kg, about 0.25 mg / kg to about 0.4 mg / kg, about 0.25 mg / kg to about 0.35 mg / kg, about 0.25 mg / kg to about 0.3 mg / kg, about 0.3 mg / kg to about 0.45 mg / kg, about 0.3 mg / kg to about 0.4 mg / kg, about 0.3 mg / kg to about 0.35 mg / kg, about 0.35 mg / kg to about 0.45 mg / kg, about 0.35 mg / kg to about 0.4 mg / kg, or about 0.4 mg / kg to about 0.45 mg / kg of infigratinib or a pharmacologic agent ... In certain embodiments, the method comprises administering about 0.01 mg / kg to about 0.15 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof to the pediatric patient. In certain embodiments, the method comprises administering about 0.01 mg / kg to about 0.3 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof to the pediatric patient.
[0136] In certain embodiments, the method comprises administering to the patient a dose of about 0.01 mg / kg to about 0.15 mg / kg, about 0.015 mg / kg to about 0.15 mg / kg, about 0.02 mg / kg to about 0.15 mg / kg, about 0.025 mg / kg to about 0.15 mg / kg, about 0.03 mg / kg to about 0.15 mg / kg, about 0.05 mg / kg to about 0.15 mg / kg, about 0.07 mg / kg to about 0.15 mg / kg, about 0.09 mg / kg to about 0.15 mg / kg, about 0.11 mg / kg to about 0.15 mg / kg, about 0.13 mg / kg to about 0.15 mg / kg , about 0.01 mg / kg to about 0.13 mg / kg, about 0.01 mg / kg to about 0.11 mg / kg, about 0.01 mg / kg to about 0.09 mg / kg, about 0.01 mg / kg to about 0.07 mg / kg, about 0.01 mg / kg to about 0.05 mg / kg, about 0.01 mg / kg to about 0.03 mg / kg, about 0.01 mg / kg to about 0.025 mg / kg, about 0.01 mg / kg to about 0.02 mg / kg, about 0.01 mg / kg to about 0.015 mg / kg, about 0.015 mg / kg to about 0.13 mg / kg, about 0.015 mg / kg to about 0. ... .11 mg / kg, about 0.015 mg / kg to about 0.09 mg / kg, about 0.015 mg / kg to about 0.07 mg / kg, about 0.015 mg / kg to about 0.05 mg / kg, about 0.015 mg / kg to about 0.03 mg / kg, about 0.015 mg / kg to about 0.025 mg / kg, about 0.015 mg / kg to about 0.02 mg / kg, about 0.02 mg / kg to about 0.13 mg / kg, about 0.02 mg / kg to about 0.11 mg / kg, about 0.02 mg / kg to about 0.09 mg / kg, about 0.02 mg / kg to about 0.07 mg / kg, about 0. 0.02mg / kg to about 0.05mg / kg, about 0.02mg / kg to about 0.03mg / kg, about 0.02mg / kg to about 0.025mg / kg, about 0.025mg / kg to about 0.13mg / kg, about 0.025mg / kg to about 0.11mg / kg, about 0.025mg / kg to about 0.09mg / kg, about 0.025mg / kg to about 0.07mg / kg, about 0.025mg / kg to about 0.05mg / kg, about 0.025mg / kg to about 0.03mg / kg, about 0.03mg / kg to about 0.13mg / kg, about 0.03mg / kg to about 0.11 mg / kg, about 0.03 mg / kg to about 0.09 mg / kg, about 0.03 mg / kg to about 0.07 mg / kg, about 0.03 mg / kg to about 0.05 mg / kg, about 0.05 mg / kg to about 0.13 mg / kg, about 0.05 mg / kg to about 0.11 mg / kg, about 0.05 mg / kg to about 0.09 mg / kg, about 0.05 mg / kg to about 0.07 mg / kg, about 0.0 The method comprises administering to the pediatric patient 7 mg / kg to about 0.13 mg / kg, about 0.07 mg / kg to about 0.11 mg / kg, about 0.07 mg / kg to about 0.09 mg / kg, about 0.09 mg / kg to about 0.13 mg / kg, about 0.09 mg / kg to about 0.11 mg / kg, or about 0.11 mg / kg to about 0.13 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof. In certain embodiments, the method comprises administering to the pediatric patient about 0.015 mg / kg to about 0.13 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof.
[0137] In certain embodiments, the method comprises administering about 0.004 mg / kg, about 0.008 mg / kg, about 0.016 mg / kg, about 0.032 mg / kg, about 0.064 mg / kg, about 0.128 mg / kg, about 0.256 mg / kg, or about 0.51 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof to a pediatric patient.
[0138] In various embodiments, provided herein are methods of treating a pediatric patient with a skeletal dysplasia, such as achondroplasia or hypochondroplasia, comprising orally administering to the patient daily about 0.1 mg to about 8 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
[0139] In certain embodiments, the method includes administering to the patient a dose of about 0.1 mg to about 8 mg, about 0.2 mg to about 8 mg, about 0.3 mg to about 8 mg, about 0.4 mg to about 8 mg, about 0.5 mg to about 8 mg, about 1 mg to about 8 mg, about 1.5 mg to about 8 mg, about 2 mg to about 8 mg, about 2.5 mg to about 8 mg, about 3 mg to about 8 mg, about 3.5 mg to about 8 mg, about 4 mg to about 8 mg, about 4.5 mg to about 8 mg, about 5 mg to about 8 mg, about 5.5 mg to about 8 mg, about 6 mg to about 8 mg, about 6.5 mg to about 8 mg, about 7 mg to about 8 mg, about 7.5 mg to about 8 mg, mg, about 0.1 mg to about 7.5 mg, about 0.1 mg to about 7 mg, about 0.1 mg to about 6.5 mg, about 0.1 mg to about 6 mg, about 0.1 mg to about 5.5 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4.5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3.5 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2.5 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1.5 mg, about 0.1 mg to about 1 mg, about 0.1 mg to about 0.5 mg, about 0.1 mg to about 0.4 mg, about 0.1 mg to about 0.3 mg, about 0.1 mg to about 0.1 mg mg to about 0.2mg, about 0.2mg to about 7.5mg, about 0.2mg to about 7mg, about 0.2mg to about 6.5mg, about 0.2mg to about 6mg, about 0.2mg to about 5.5mg, about 0.2mg to about 5mg, about 0.2mg to about 4.5mg, about 0.2mg to about 4mg, about 0.2mg to about 3.5mg, about 0.2mg to about 3mg, about 0.2mg to about 2.5mg, about 0.2mg to about 2mg, about 0.2mg to about 1.5mg, about 0.2mg to about 1mg, about 0.2mg to about 0.5mg, about 0.2mg to about 0.4mg, about 0.2mg to about 0. 3mg, about 0.3mg to about 7.5mg, about 0.3mg to about 7mg, about 0.3mg to about 6.5mg, about 0.3mg to about 6mg, about 0.3mg to about 5.5mg, about 0.3mg to about 5mg, about 0.3mg to about 4.5mg, about 0.3mg to about 4mg, about 0.3mg to about 3.5mg, about 0.3mg to about 3mg, about 0.3mg to about 2.5mg, about 0.3mg to about 2mg, about 0.3mg to about 1.5mg, about 0.3mg to about 1mg, about 0.3mg to about 0.5mg, about 0.3mg to about 0.4mg, about 0.4mg to about 7.5mg, about 0.4 mg to about 7 mg, about 0.4 mg to about 6.5 mg, about 0.4 mg to about 6 mg, about 0.4 mg to about 5.5 mg, about 0.4 mg to about 5 mg, about 0.4 mg to about 4.5 mg, about 0.4 mg to about 4 mg, about 0.4 mg to about 3.5 mg, about 0.4 mg to about 3 mg, about 0.4 mg to about 2.5 mg, about 0.4 mg to about 2 mg, about 0.4 mg to about 1.5 mg, about 0.4 mg to about 1 mg, about 0.4 mg to about 0.5 mg, about 0.5 mg to about 7.5 mg, about 0.5 mg to about 7 mg, about 0.5 mg to about 6.5 mg, about 0.5 mg to about 6 mg, about 0.5mg to about 5.5mg, about 0.5mg to about 5mg, about 0.5mg to about 4.5mg, about 0.5mg to about 4mg, about 0.5mg to about 3.5mg, about 0.5mg to about 3mg, about 0.5mg to about 2.5mg, about 0.5mg to about 2mg, about 0.5mg to about 1.5mg, about 0.5mg to about 1mg, about 1.5mg to about 7.5mg, about 1.5mg to about 7mg, about 1.5mg to about 6.5mg, about 1.5mg to about 6mg, about 1.5mg to about 5.5mg, about 1.5mg to about 5mg, about 1.5mg to about 4.5mg, about 1.5mg to about 4mg g, about 1.5 mg to about 3.5 mg, about 1.5 mg to about 3 mg, about 1.5 mg to about 2.5 mg, about 1.5 mg to about 2 mg, about 2 mg to about 7.5 mg, about 2 mg to about 7 mg, about 2 mg to about 6.5 mg, about 2 mg to about 6 mg, about 2 mg to about 5.5 mg, about 2 mg to about 5 mg, about 2 mg to about 4.5 mg, about 2 mg to about 4 mg, about 2 mg to about 3.5 mg, about 2 mg to about 3 mg, about 2 mg to about 2.5 mg, about 2.5 mg to about 7.5 mg, about 2.5 mg to about 7 mg, about 2.5 mg to about 6.5 mg, about 2.5 ... .5mg to about 5.5mg, about 2.5mg to about 5mg, about 2.5mg to about 4.5mg, about 2.5mg to about 4mg, about 2.5mg to about 3.5mg, about 2.5mg to about 3mg, about 3mg to about 7.5mg, about 3mg to about 7mg, about 3mg to about 6.5mg, about 3mg to about 6mg, about 3mg to about 5.5mg, about 3mg to about 5mg, about 3mg to about 4.5mg, about 3mg to about 4mg, about 3mg to about 3.5mg, about 3.5mg to about 7.5mg, about 3.5mg to about 7mg, about 3.5mg to about 6.5mg, about 3.5mg to about 6mg, about 3.5mg to about 5.5mg, about 3.5mg to about 5mg, about 3.5mg to about 4.5mg, about 3.5mg to about 4mg, about 4mg to about 7.5mg, about 4mg to about 7mg, about 4mg to about 6.5mg, about 4mg to about 6mg, about 4mg to about 5.5mg, about 4mg to about 5mg, about 4mg to about 4.5mg, about 4.5mg to about 7.5mg, about 4.5mg to about 7mg, about 4.5mg to about 6.5mg, about 4.5mg to about 6mg, about 4.5mg to about 5.5mg, about 4.5mg to about 5mg, about 5mg In certain embodiments, the method comprises administering from about 0.1 mg to about 7 mg of infigratinib or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering from about 0.1 mg to about 7 mg of infigratinib or a pharmaceutically acceptable salt thereof.
[0140] In certain embodiments, the method comprises administering about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, or about 8 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
[0141] In certain embodiments, the pediatric patient has an FGFR3 mutation. In certain embodiments, the FGFR3 mutation is a G380R mutation.
[0142] In certain embodiments, infigratinib or a pharmaceutically acceptable salt thereof is administered in the form of a mini-tablet. In certain embodiments, infigratinib or a pharmaceutically acceptable salt thereof is administered in the form of a mini-tablet as described herein. In certain embodiments, infigratinib or a pharmaceutically acceptable salt thereof is administered as a mini-tablet, each of which has about 0.1 mg or about 1 mg of infigratinib or a pharmaceutically acceptable salt thereof. In certain embodiments, infigratinib or a pharmaceutically acceptable salt thereof is administered as a mini-tablet, each of which has about 0.1 mg or about 1 mg of infigratinib or a pharmaceutically acceptable salt thereof.
[0143] In certain embodiments, infigratinib is present in the mini-tablets as infigratinib monophosphate. In certain embodiments, infigratinib monophosphate is present as an anhydrous crystalline form. In certain embodiments, the anhydrous crystalline form of infigratinib monophosphate is characterized by an XRPD peak at 15.0°±0.2° (2θ).
[0144] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase in height velocity relative to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% increase in height velocity relative to baseline.
[0145] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an increase over baseline in anthropometric measurements selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof. In certain embodiments, after daily administration of a dose of infigratinib or a pharmacologic acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% increase over baseline in an anthropometric measurement selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span and combinations thereof.
[0146] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an absolute increase in anthropometric measurements selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof. In certain embodiments, after daily administration of doses of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an absolute increase in an anthropometric measurement selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100%.
[0147] In certain embodiments, after administering a daily dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a reduction in body weight compared to baseline. In certain embodiments, after administering a daily dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% reduction in body weight compared to baseline.
[0148] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute reduction in body weight. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an absolute reduction in body weight of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%.
[0149] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient shows a proportional increase in head circumference relative to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient shows an absolute proportional increase in head circumference. For example, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the trunk may become proportional to the head. In contrast, in the absence of treatment with infigratinib or a pharmaceutically acceptable salt thereof, the patient may have macrocephaly.
[0150] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient shows normalization of body ratio measurement ratio compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient shows absolute normalization of body ratio measurement ratio. For example, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the limbs may grow more proportionally compared to the trunk. In contrast, in the absence of treatment with infigratinib or a pharmaceutically acceptable salt thereof, the patient may have disproportionately short limbs compared to the trunk.
[0151] In certain embodiments, the body ratio measurement ratio is selected from the group consisting of upper to lower body body part ratio, upper arm to forearm ratio, upper limb length ratio to lower limb length ratio, arm span to standing height ratio, head circumference to standing height ratio, and combinations thereof.
[0152] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase compared to baseline in a biomarker of bone metabolism selected from the group consisting of collagen X degradation fragments, collagen X markers, and combinations thereof. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% increase compared to baseline in a biomarker of bone metabolism selected from the group consisting of collagen X degradation fragments, collagen X markers, and combinations thereof.
[0153] In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase in exercise capacity compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits an increase in exercise capacity of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% relative to baseline.
[0154] In certain embodiments, after administering a daily dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a reduction in the number of episodes of otitis media versus baseline. In certain embodiments, after administering a daily dose of infigratinib or a pharmaceutically acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% reduction in the number of episodes of otitis media versus baseline.
[0155] In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits a reduction in the number and / or severity of sleep apnea episodes compared to baseline. In certain embodiments, after daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95% or 100% reduction in the number and / or severity of sleep apnea episodes compared to baseline.
[0156] In certain embodiments, after administration of daily doses of infigratinib or a pharma- ceutically acceptable salt thereof, the pediatric patient exhibits an increase in QOL, as assessed using the Pediatric Quality of Life Inventory.
[0157] In certain embodiments, a pediatric patient is 2 years old or younger, 3 years old or younger, 4 years old or younger, 5 years old or younger, 6 years old or younger, 7 years old or younger, 8 years old or younger, 9 years old or younger, 10 years old or younger, 11 years old or younger, 12 years old or younger, 13 years old or younger, 14 years old or younger, 15 years old or younger, 16 years old or younger, 17 years old or younger, 18 years old or younger, 19 years old or younger, 20 years old or younger, or 21 years old or younger. In certain embodiments, a pediatric patient is 12 years old or younger.
[0158] In certain embodiments, the pediatric patient is between 2 and 21 years of age, between 3 and 21 years of age, between 4 and 21 years of age, between 5 and 21 years of age, between 6 and 21 years of age, between 7 and 21 years of age, between 8 and 21 years of age, between 9 and 21 years of age, between 10 and 21 years of age, between 11 and 21 years of age, between 12 and 21 years of age, between 13 and 21 years of age, between 14 and 21 years of age, between 15 and 21 years of age, between 16 and 21 years of age, between 17 and 21 years of age, between 18 and 21 years of age, between 19 and 21 years of age, between 20 and 21 years of age, between 2 and 20 years of age, between 2 and 19 years of age, between 2 and 18 years of age, between 2 and 17 years of age, between 2 and 16 years of age, between 2 and 15 years of age, between 2 and 14 years of age, between 2 and 13 years of age, between 2 and 12 years of age, years old, 2 to 11 years old, 2 to 10 years old, 2 to 9 years old, 2 to 8 years old, 2 to 7 years old, 2 to 6 years old, 2 to 5 years old, 2 to 4 years old, 2 to 3 years old, 3 to 20 years old, 3 to 19 years old, 3 to 18 years old, 3 to 17 years old, 3 to 16 years old, 3 to 15 years old, 3 to 14 years old, 3 to 13 years old, 3 to 12 years old, 3 to 11 years old, 3 to 10 years old, 3 to 9 years old, 3 to 8 years old, 3 to 7 years old, 3 to 6 years old, 3 to 5 years old, 3 to 4 years old, 4 to 20 years old, 4 to 19 years old, 4 to 18 years old, 4 to 17 years old, 4 to 16 years old, 4 to 15 years old, 4 to 1 years old 4 years old, 4 to 13 years old, 4 to 12 years old, 4 to 11 years old, 4 to 10 years old, 4 to 9 years old, 4 to 8 years old, 4 to 7 years old, 4 to 6 years old, 4 to 5 years old, 5 to 20 years old, 5 to 19 years old, 5 to 18 years old, 5 to 17 years old, 5 to 16 years old, 5 to 15 years old, 5 to 14 years old, 5 to 13 years old, 5 to 12 years old, 5 to 11 years old, 5 to 10 years old, 5 to 9 years old, 5 to 8 years old, 5 to 7 years old, 5 to 6 years old, 6 to 20 years old, 6 to 19 years old, 6 to 18 years old, 6 to 17 years old, 6 to 16 years old, 6 to 15 years old, 6 to 14 years old, 6 to 13 years old, 6 to 12 years old, 6 to 11 years old, 6 to 10 years old, 6 to 9 years old, 6 to 8 years old, 6 to 7 years old, 7 to 20 years old, 7 to 19 years old, 7 to 18 years old, 7 to 17 years old, 7 to 16 years old, 7 to 15 years old, 7 to 14 years old, 7 to 13 years old, 7 to 12 years old, 7 to 11 years old, 7 to 10 years old, 7 to 9 years old, 7 to 8 years old, 8 to 20 years old, 8 to 19 years old, 8 to 18 years old, 8 to 17 years old, 8 to 16 years old, 8 to 15 years old, 8 to 14 years old, 8 to 13 years old, 8 to 12 years old, 8 to 11 years old, 8 to 10 years old, 8 to 9 years old, 9 to 20 years old,9 to 19 years old, 9 to 18 years old, 9 to 17 years old, 9 to 16 years old, 9 to 15 years old, 9 to 14 years old, 9 to 13 years old, 9 to 12 years old, 9 to 11 years old, 9 to 10 years old, 10 to 20 years old, 10 to 19 years old, 10 to 18 years old, 10 to 17 years old, 10 to 16 years old, 10 to 15 years old, 10 to 14 years old, 1 0 to 13 years old, 10 to 12 years old, 10 to 11 years old, 11 to 20 years old, 11 to 19 years old, 11 to 18 years old, 11 to 17 years old, 11 to 16 years old, 11 to 15 years old, 11 to 14 years old, 11 to 13 years old, 11 to 12 years old, 12 to 20 years old, 12 to 19 years old, 12 to 18 years old, 12 to 17 years old, 12 ages 12 to 16, ages 12 to 15, ages 12 to 14, ages 12 to 13, ages 13 to 20, ages 13 to 19, ages 13 to 18, ages 13 to 17, ages 13 to 16, ages 13 to 15, ages 13 to 14, ages 14 to 20, ages 14 to 19, ages 14 to 18, ages 14 to 17, ages 14 to 16, ages 14 In certain embodiments, the pediatric patient is between 3 and 15 years of age, 15 and 20 years of age, 15 and 19 years of age, 15 and 18 years of age, 15 and 17 years of age, 15 and 16 years of age, 16 and 20 years of age, 16 and 19 years of age, 16 and 18 years of age, 16 and 17 years of age, 17 and 20 years of age, 17 and 19 years of age, 17 and 18 years of age, 18 and 20 years of age, 18 and 19 years of age, or 19 and 20 years of age. In certain embodiments, the pediatric patient is between 3 and 11 years of age.
[0159] In certain embodiments, a pediatric patient is under the age of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21. In certain embodiments, a pediatric patient is under the age of 8.
[0160] In certain embodiments, the pediatric patient is 2 years of age or older, 3 years of age or older, 4 years of age or older, 5 years of age or older, 6 years of age or older, 7 years of age or older, 8 years of age or older, 9 years of age or older, 10 years of age or older, 11 years of age or older, 12 years of age or older, 13 years of age or older, 14 years of age or older, 15 years of age or older, 16 years of age or older, 17 years of age or older, 18 years of age or older, 19 years of age or older, or 20 years of age or older. In certain embodiments, the pediatric patient is 8 years of age or older.
[0161] In certain embodiments, the methods provided herein further comprise administering to the patient an effective amount of a second therapeutic agent. EXAMPLES
[0162] In order that the disclosure herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described herein are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein, but are not to be construed as in any way limiting the scope thereof.
[0163] Example 1: Synthesis of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-4-(4-ethyl-piperazin-1-yl)-phenylaminol-pyrimidin-4-yl}-1-methyl-urea (Infigratinib) Step A: Synthesis of N-4-(4-ethyl-piperazin-1-yl)-phenyl)-N'-methyl-pyrimidine-4,6-diamine A mixture of 4-(4-ethylpiperazin-1-yl)-aniline (1 g, 4.88 mmol), (6-chloro-pyrimidin-4-yl)-methyl-amine (1.81 g, 12.68 mmol, 1.3 eq.) and 4N HCl in dioxane (15 mL) is heated to 150° C. for 5 h in a sealed tube. The reaction mixture is concentrated and diluted with dichloromethane (DCM) and saturated aqueous sodium bicarbonate solution. The aqueous layer is separated and extracted with DCM. The organic phase is washed with brine, dried (sodium sulfate), filtered and concentrated. The residue is purified by silica gel column chromatography (DCM / MeOH, 93:7) followed by trituration in diethyl ether to give the title compound as a white solid. ESI-MS: 313.2 [MH] + ;t R = 1.10 min (gradient J); TLC: R f = 0.21 (DCM / MeOH, 93:7).
[0164] Step B: Synthesis of 4-(4-ethylpiperazin-1-yl)-aniline A suspension of 1-ethyl-4-(4-nitro-phenyl)-piperazine (6.2 g, 26.35 mmol) and Raney Nickel (2 g) in MeOH (120 mL) is stirred under hydrogen atmosphere at RT for 7 h. The reaction mixture is filtered through a Celite pad to give 5.3 g of the title compound as a violet solid. ESI-MS: 206.1 [MH] + ;TLC:R f =0.15(DCM / MeOH+1%NH3 aq , 9:1).
[0165] Step C: Synthesis of 1-ethyl-4-(4-nitro-phenyl)-piperazine A mixture of 1-bromo-4-nitrobenzene (6 g, 29.7 mmol) and 1-ethylpiperazine (7.6 mL, 59.4 mmol, 2 eq.) is heated to 80° C. for 15 h. After cooling to RT, the reaction mixture is diluted with water and DCM / MeOH, 9:1. The aqueous layer is separated and extracted with DCM / MeOH, 9:1. The organic phase is washed with brine, dried (sodium sulfate), filtered and concentrated. Silica gel column chromatography (DCM / MeOH+1% NH3 aq , 9:1) to give 6.2 g of the title compound as a yellow solid. ESI-MS: 236.0 [MH] + ;t R = 2.35 min (purity: 100%, gradient J); TLC: R f =0.50(DCM / MeOH+1%NH3 aq , 9:1).
[0166] Step D: Synthesis of (6-chloro-pyrimidin-4-yl)-methyl-amine This material was prepared by a modified procedure published in the literature (J. Appl. Chem. 1955, 5, 358). To a suspension of commercially available 4,6-dichloropyrimidine (20 g, 131.6 mmol, 1.0 eq.) in isopropanol (60 mL) is added 33% methylamine in ethanol (40.1 mL, 328.9 mmol, 2.5 eq.) at such a rate that the internal temperature does not rise above 50° C. After the addition is complete, the reaction mixture is stirred at room temperature for 1 h. Water (50 mL) is then added and the formed suspension is cooled to 5° C. in an ice bath. The precipitated product is filtered off and washed with cold isopropanol / water 2:1 (45 mL) and water. The collected material is dried under vacuum at 45° C. overnight to give the title compound as a colorless powder. R =3.57min (purity:>99%, gradient A), ESI-MS: 144.3 / 146.2[MH] + .
[0167] Step E: Synthesis of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-4-(4-ethyl-piperazin-1-yl)-phenylaminol-pyrimidin-4-yl}-1-methyl-urea) The title compound was prepared by adding 2,6-dichloro-3,5-dimethoxyphenyl-isocyanate (1.25 eq.) to a solution of N-4-(4-ethyl-piperazin-1-yl)-phenyl)-N'-methyl-pyrimidine-4,6-diamine (2.39 g, 7.7 mmol, 1 eq.) in toluene and stirring the reaction mixture at reflux for 1.5 h. Column chromatography on silica gel (DCM / MeOH+1% NH3 aq , 95:5) to give the title compound as a white solid. ESI-MS: 560.0 / 561.9 [MH] + ;t R = 3.54 min (purity: 100%, gradient J); TLC: R f =0.28(DCM / MeOH+1%NH3 aq , 95:5). Analysis:C 26 H 31N7O3Cl2, calculated values: C, 55.72%; H, 5.57%; N, 17.49%; O, 8.56%; Cl, 12.65%. Found values: C, 55.96%; H, 5.84%; N, 17.17%; O, 8.46%; Cl, 12.57%.
[0168] Example 2: Synthesis of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-4-(4-ethyl-piperazin-1-yl)-phenylaminol-pyrimidin-4-yl}-1-methyl-urea monophosphate form A (BGJ398) A round bottom flask was charged with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-4-(4-ethylpiperazin-1-yl)phenylaminol-pyrimidin-4-yl)-1-methyl-urea (134 g, 240 mmol) and isopropanol (IPA) (2000 mL). The suspension was stirred and heated to 50° C., and to it was added a solution of phosphoric acid (73.5 g, 750 mmol) in water (2000 mL). The mixture was stirred at 60° C. for 30 min and filtered through a polypropylene pad. The pad was washed with warm IPA / water (1:1, 200 mL) and the filtrates were combined. To this clear solution was added IPA (6000 mL) and the mixture was stirred under reflux for 20 min, gradually cooled to room temperature (25° C.) and stirred for 24 h. The white salt product was collected by filtration, washed with IPA (2×500 mL) and dried in an oven at 60° C. under reduced pressure for 2 days to give the anhydrous crystalline monophosphate salt (110 g). Yield 70%. Purity by HPLC >98%. Analysis: C 26 H 34 N7O7Cl2P, calculated values: C, 47.42%; H, 5.20%; N, 14.89%; O, 17.01%; Cl, 10.77%; P, 4.70%. Found values: C, 47.40%; H, 5.11%; N, 14.71%; O, 17.18%; Cl, 10.73%; P, 4.87%.
[0169] Example 3: 0.1 mg and 1 mg doses of infigratinib monophosphate minitablets The examples below outline the manufacturing process for all exemplary dosage strengths.
[0170] The corresponding amounts of ingredients are provided in the formulations below under Examples 3.1, 3.2, 3.3, and 3.4.
[0171] Mini-tablet manufacturing For 0.1 mg and 1.0 mg infigratinib mini-tablets having the formulations listed in Example 3.1 (Table 1) and Example 3.3 (Table 3) respectively, the manufacturing process consists of wet granulation, blending and compression with the following steps for an example batch size of 5000 g: · Add povidone to the purified water dispensed in the container and mix until the povidone dissolves to form a binder solution. · Pass the intragranular mannitol, microcrystalline cellulose, and crospovidone through a #30 mesh screen. Mannitol and microcrystalline cellulose should be used in four and three parts, respectively. · Charge mannitol (part 1) and microcrystalline cellulose (part 1) into a high shear granulator and mix for 5 minutes at an impeller speed of 100 rpm. Mill infigratinib phosphate (BGJ398 API) and mannitol (portion 2) through a #60 mesh screen for 0.1 mg infigratinib mini-tablets or a #50 mesh screen for 1.0 mg infigratinib mini-tablets. · Add the screened API, the mannitol (part 2), and the MCC (part 2) to a high shear granulator and mix for 5 minutes at an impeller speed of 100 rpm. · Add mannitol (part 3) to the high shear granulator and mix for 5 minutes at an impeller speed of 100 rpm. · Add the remaining mannitol, microcrystalline cellulose, and intragranular crospovidone to the high shear granulator and mix for 5 minutes at an impeller speed of 150 rpm. ·Turn the high shear granulator "on" with an impeller speed of 150 rpm and spray the binder solution for approximately 1 minute. After completion of binder solution addition, mix the wet mass for 30 seconds with impeller speed of 150 rpm. · Mix the wet mass for a further 30 seconds with impeller speed of 150 rpm and chopper speed of 1500 rpm. -Until LOD reaches NMT2%, the inlet air temperature is approximately 60°C and the flow rate is approximately 250m 3 Dry the wet granules in a suitable size fluid bed dryer with an air volume of 10000 / h. · Mill the dry granules through a Quadro Comil equipped with a 2A032R screen at a speed of approximately 1500 rpm. Pass the extragranular crospovidone through a #30 mesh screen and FD&C Blue #1 / Brilliant Blue FCF Aluminum Lake through a #80 mesh screen (FD&C Blue #1 only for the 1.0 mg infigratinib minitablets). Load the milled granules, extragranular crospovidone, and FD&C Blue #1 / Brilliant Blue FCF Aluminum Lake (FD&C Blue #1 only for the 1.0 mg infigratinib mini-tablets) into an appropriate size bin blender and blend for 5 minutes at 26 rpm. · Magnesium stearate, screened through a #40 mesh screen, is added to the blender and mixed for 5 minutes at 26 rpm and discharged as the final blend. Compress the final blend using a suitable press into mini tablets using 2.2mm round tooling. For 0.1 mg infigratinib minitablets having the formulation of Example 3.1 (Table 2), the manufacturing process consists of dry blending and compression with the following steps for an example batch size of 5000 g: · Screen the milled API through a #50 mesh screen and dispense the screened API into a double polyethene bag lined container. Screen the mannitol, microcrystalline cellulose, and croscarmellose sodium through a #30 mesh screen. Split the screened mannitol into three portions and the microcrystalline cellulose into two portions. · Add Mannitol (part 1) into the bag containing the screened milled API and mix manually for 1 minute. · Transfer the above mixture into a suitable size V blender and blend for 10 minutes. · Add screened microcrystalline cellulose (part 1) into the blender and blend for 10 minutes. Discharge the blend and screen through a #30 mesh screen and load the blend back into the blender. · Add screened mannitol (part 2) into the blender and blend for 10 minutes. Discharge the blend and screen through a #30 mesh screen and load the blend back into the blender. · Add screened microcrystalline cellulose (part 2) into the blender and blend for 10 minutes. Discharge the blend from the blender, screen the blend through a #30 mesh, and then load the blend back into the blender. · Add screened croscarmellose sodium to the blender and blend for 10 minutes. Pass the Magnesium Stearate through a #40 mesh screen and load it into the blender. Blend for 3 minutes at 21 rpm and discharge as the final blend. · Compress the final blend into mini tablets using 2mm round tooling. For 1.0 mg infigratinib minitablets having the formulation listed in Example 3.4 (Table 4), the manufacturing process consists of dry granulation, blending, and compression with the following steps for an example batch size of 5000 g: · Screen the milled API through a #50 mesh screen and dispense the screened API into a double polyethene bag lined container. Screen the intragranular portions of Mannitol, Microcrystalline Cellulose, Croscarmellose Sodium through a #30 mesh screen, and FD&C Blue #1 / Brilliant Blue FCF Aluminum through a #50 mesh screen and place separately into a polybag lined container with suitable label. · Load the mannitol, milled API, FD&C Blue #1 / Brilliant Blue FCF Aluminum, microcrystalline cellulose, and intragranular portion of croscarmellose sodium into an appropriate size V-blender and blend for 10 minutes at 21 rpm. Discharge the blend and screen the blend using a #30 mesh screen into a container lined with an LDPE bag. Load the screened blend into the blender and blend for 5 minutes at 21 rpm. Pass the magnesium stearate through a #40 mesh screen and collect in a stainless steel pan. Add the screened magnesium stearate to the blender. Blend for 3 minutes at 21 rpm. The blend is granulated by passing it through a roller compactor to achieve a continuous stream of brittle ribbons. The milled granules are collected in a tared double PE bag lined container. Screen the extragranular portions of microcrystalline cellulose and croscarmellose sodium using a #30 mesh screen. · Charge half of the dry granules, the extragranular microcrystalline cellulose, the extragranular croscarmellose sodium, and the remainder of the dry granules into a suitable V-blender and blend for 7 minutes at 21 rpm. · Screen the extragranular magnesium stearate through a #40 mesh screen, add to the V blender and blend for 5 minutes at 21 rpm and discharge as the final blend. · Compress the final blend into mini tablets using 2mm round tooling. [Table 1] [Table 2] [Table 3] [Table 4]
[0172] Example 4: Study of Oral Infigratinib Monophosphate (BGJ398) in Pediatric Patients with Achondroplasia the purpose Dose Escalation: Primary Objective: To identify a dose of oral infigratinib based on safety and efficacy evaluations for children with achondroplasia (ACH) to be used in further studies.
[0173] Dose Expansion: Primary Objective: To provide preliminary evidence of efficacy of oral infigratinib for the treatment of ACH, as assessed by change from baseline in height velocity in children with ACH.
[0174] Dose Escalation and Expansion: Secondary Objectives: To assess the safety and tolerability of oral infigratinib in children with ACH, to assess the change from baseline in anthropometric parameters following administration of oral infigratinib, and to assess the pharmacokinetic and pharmacodynamic (PK / PD) profile of infigratinib in children with ACH following administration of oral infigratinib.Exploratory Objective: To assess the change in ACH disease burden.
[0175] method To evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3 selective tyrosine kinase inhibitor, in children 3 to 11 years of age with ACH who have previously received infigratinib for at least 6 months. The study will include dose escalation and dose expansion with long-term treatment.
[0176] Dose escalation for long-term treatment (total of 18 months treatment and follow-up): Eligible subjects aged 3 to 11 years will be enrolled in ascending dose cohorts of approximately 10 subjects. The proportion of subjects <8 years and >=8 years will be approximately balanced between cohorts.
[0177] Up to four cohorts are planned, with each cohort beginning after the previous dose is deemed safe by the Data review committee (DRC) based on prespecified criteria (see Cohort Dose Escalation and Cohort Dose De-Escalation below). In the United States (US), subjects will begin enrolling in cohorts 3 and 4 (i.e., no subjects from the US will be enrolled in cohorts 1 or 2).
[0178] Subjects in each cohort will be treated and followed up for 6 months at their assigned dose. After the 6-month study visit, subjects will continue to receive treatment for an additional 12 months (long-term treatment period). To avoid long-term treatment with potentially ineffective or insufficient doses, subjects in cohorts 1 and 2 will receive doses escalated to the next dose level at their 6-month and 12-month study visits (up to 2 dose escalations allowed) if no safety concerns are identified and their annual height velocity does not increase by at least 25% above baseline (not applicable in the United States). If the dose identified for further study has not been determined by the time the subject reaches 12 months of treatment, a dose escalation will occur at 12 months. When this dose is determined, subjects in all cohorts may receive doses adjusted to the dose identified for further study. After all subjects have had the opportunity to complete 6 months of infigratinib treatment, the dose identified for further study will be selected based on a thorough review of efficacy and safety findings from dose escalation.
[0179] Dose Expansion (12 months total treatment): To support and validate the identified dose / dose regimen for further testing, 20 subjects will be enrolled in a dose expansion and will receive infigratinib treatment at the identified dose for 12 months.
[0180] All subjects: After completing study activities, all subjects will have the opportunity to enroll in an open-label, long-term extension study (administered under a separate protocol) to assess the safety and efficacy of long-term administration of infigratinib in children with ACH.
[0181] Determination of starting dose and other cohort doses Starting dose: The starting dose for this Phase 2 study is based on the no observed adverse effect level (NOAEL) from a juvenile toxicity study in rats with a 10-fold safety margin. In the United States, the study will begin in cohort 3, corresponding to a dose that also takes into account an estimate of the pharmacologically active dose based on studies performed in a mouse model similar to achondroplasia.
[0182] Other dose cohorts: After safety in the historical cohorts has been confirmed by a Data review committee (DRC), the escalating dose cohorts will be initiated. Each successive dose will be twice the previous dose. In the United States, the cohort 4 dose will be twice the dose administered in cohort 3. Dose cohort de-escalation will be based on pre-specified criteria for safety reasons (see Cohort Dose Escalation and Cohort Dose De-escalation below).
[0183] Number of subjects Approximately 60 subjects in total will be enrolled: 40 subjects in dose escalation and 20 subjects in dose expansion of long-term treatment.
[0184] Diagnosis and Key Selection Criteria Selection criteria: 1. Informed consent signed by the subject or parent or legally authorized representative (LAR) and informed consent signed by the subject (when applicable). 2.Age 3 to 11 years (inclusive) at time of screening. 3. Clinically confirmed and genetically confirmed diagnosis of ACH. 4. At least 6 months of growth assessment in the PROPEL study (protocol QBGJ398-001) prior to study entry. 5. Able to walk and stand without assistance. 6. If the girl is ≥ 10 years old, a negative pregnancy test. 7. If sexually active, be willing to use highly effective contraception while taking study medication and for 3 months after the last dose of study medication. 8. Subject and parent or LAR are willing and able to comply with study visits and procedures. 9. Able to swallow oral medications. 10. Willing to stop consuming, and have not consumed, grapefruit, grapefruit juice, grapefruit hybrids, pomegranate, starfruit, pomelo, Seville orange, or products containing the juice of these fruits within 7 days prior to the first dose of study medication.
[0185] Exclusion criteria: 1. Hypochondroplasia or short stature conditions other than ACH (e.g., trisomy 21, pseudoachondroplasia, psychosocial short stature). 2. Female and have had their first period. 3. Height <-2 or >+2 standard deviations for age and sex based on reference tables for growth in children with ACH (Horton 1978). 4. Annual height velocity ≤ 1.5 cm / year for a period of ≥ 6 months prior to screening. 5. Significant intercurrent disease or condition that, in the investigator's and / or sponsor's view, may confound the assessment of efficacy or safety of infigratinib, including but not limited to the following: Heart or vascular disease Significant ECG abnormalities, such as previous myocardial infarction, left ventricular hypertrophy, flat T waves (especially in inferior leads) or minor nonspecific ST-T wave changes, QRS >90 msec, QT interval corrected using Fridericia's formula (QTcF) >440 msec, PR interval >170 msec, or evidence of complete right or left bundle branch block ·Hyperthyroidism Abnormal thyroid levels or recently diagnosed hypothyroidism that have not been stable to therapy for at least 3 months Uncontrolled (HbA1c>9%) or insulin-requiring diabetes Adrenal insufficiency ·Autoimmune inflammatory diseases ·Inflammatory bowel disease Severe sleep apnea requiring surgery or new use of a continuous positive airway pressure (CPAP) machine (based on a screening sleep study) 6. Significantly abnormal screening laboratory results, including but not limited to: Hemoglobin < 10.0 g / dL. b. Total bilirubin >1.5 × upper limit of normal (ULN). c. AST / SGOT or ALT / SGPT > 2 × ULN. d. Calculated or measured creatinine clearance <60 mL / min. 7. Current evidence of corneal or retinal disorder / keratopathy, including but not limited to bullous / band keratopathy, corneal abrasion, inflammation / ulceration, or keratoconjunctivitis as confirmed by ophthalmologic examination. 8. History and / or current evidence of extensive ectopic tissue calcification. 9. History of malignant lesions. 10. Current use of medications known to prolong the QT / QTc interval (within 7 days or 5 half-lives [whichever is longer] prior to the screening visit) or treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications that increase serum phosphorus and / or calcium concentrations. Subjects are not permitted to take vitamin D analogs, medications that alter the pH of the gastrointestinal tract (including antacids, H2 antagonists (e.g., ranitidine), and proton pump inhibitors (e.g., omeprazole)), or enzyme-inducing antiepileptic drugs (including carbamazepine, phenytoin, phenobarbital, and primidone). 11. Current evidence of endocrine alteration of calcium / phosphorus homeostasis: A. Inorganic phosphorus outside normal limits. b. Total serum calcium (corrected) outside normal limits. 12. Allergy to any component of the study medication. 13. Treatment with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the past 6 months or long-term treatment (>3 months) at any time. 14. Treatment with C-type natriuretic peptide (CNP) analogues, fibroblast growth factor (FGF) ligand traps, or targeted FGFR inhibition at any time. 15. Supraphysiological doses of glucocorticoid therapy (i.e., >15 mg / m 2 Regular long-term treatment (≧3 weeks) with 0.001 / day hydrocortisone or equivalent or treatment with glucocorticoids in anti-inflammatory doses for more than 3 weeks within 6 months of the screening visit (low-dose continuous inhaled steroids for asthma are acceptable). 16. Treatment with any other investigational product or investigational medical device for the treatment of ACH or short stature. 17. Previous leg lengthening surgery or guided growth surgery. 18. Fracture within 6 months of screening (due to potential effects on bone biomarkers and bone morphology).
[0186] Test article, dose, and mode of administration The following four dose cohorts will be used: Cohort 1: 0.016 mg / kg Cohort 2: 0.032 mg / kg Cohort 3: 0.064 mg / kg Cohort 4: 0.128 mg / kg
[0187] Outside the US, infigratinib will be offered orally at a starting dose of 0.016 mg / kg QD, corresponding to one-tenth of the preclinical NOAEL (cohort 1). In the US, trials will begin in cohort 3 (0.064 mg / kg), corresponding to a dose that also takes into account an estimate of the pharmacologically active dose based on studies performed in a mouse model resembling achondroplasia.
[0188] Endpoints Dose escalation: primary endpoint Treatment-emergent adverse events (TEAEs) leading to dose reduction or discontinuation. Change from baseline in height velocity (annualized in cm / year). (Baseline is defined as annualized height velocity from the minimum of 6 months of observation in the PROPEL study.)
[0189] Dose expansion: Primary endpoint Change from baseline in height velocity (annualized in cm / year).
[0190] Dose escalation and expansion: secondary endpoints Safety assessments including incidence, type, severity, and causality of adverse events (AEs), serious adverse events (SAEs), laboratory test results (urinalysis, chemistry, hematology), clinically significant changes in vital signs, physical examination (including ophthalmologic and dental evaluations), electrocardiograms, and imaging. Absolute height velocity (annualized in cm / year) expressed numerically and as z-scores in relation to non-ACH tables. Changes from baseline in absolute quantities (expressed as absolute values and z-scores in relation to ACH and non-ACH standardized pediatric growth curves) and anthropometric parameters (including body proportions). Anthropometric measurements may include, but are not limited to, height, sitting height, weight, head circumference, upper and lower arm lengths, thigh length, knee height, and arm span. Body ratio measurement ratios may include, but are not limited to, upper body to lower body segment ratios, upper arm to lower arm length ratios, upper leg to lower leg length ratios, arm span to height ratios, and head circumference to height ratios. PK parameters (for example, C max and t max ) Changes in PD parameters (biomarkers of bone metabolism that may include type X collagen degradation fragments, collagen X marker [CXM]).
[0191] Dose Escalation and Dose Expansion: Exploratory Endpoints Changes in disease-specific complications, e.g., change in mobility (assessed by range of motion of elbows, hips, and knees), change in number of episodes of otitis media / year, change in number and / or severity of episodes of sleep apnea, and change in quality of life [QoL] assessed by PedsQL (Generic Core Scales Short Form, child and parent report). -Baseline range of motion and PedsQL will correspond to values obtained at the baseline examination. The number of episodes recorded during the PROPEL trial [expressed as episodes / year] will serve as the baseline number of otitis media episodes. Baseline sleep apnea corresponds to polysomnogram performed at screening [to exclude severe sleep apnea].
[0192] Data review committee (DRC), cohort dose escalation, cohort dose deescalation, individual subject dose reduction / discontinuation Data review committee (DRC) The study will utilize a DRC to monitor subject safety and primary efficacy data and provide recommendations to the sponsor regarding escalation, de-escalation, and / or expansion of dose cohorts. Cohort dose escalation and de-escalation will be determined by the DRC based on a Bayesian optimal interval (BOIN) design (Liu 2015) with a target toxicity rate of 25%.
[0193] Cohort Dose Escalation Each cohort is initiated after the safety of the previous dose cohort (ECG, vital signs, physical exam, TEAE assessment, and clinical laboratories) has been reviewed and confirmed by the DRC. During dose escalation, initiation of a new escalating dose cohort is determined by the DRC based on review of safety data from approximately 10 subjects in each cohort after completing at least 4 weeks of treatment and safety assessments. After at least 4 weeks of treatment, if ≦1 / 10 subjects meet dose reduction / discontinuation criteria (see below for individual subject dose reduction / discontinuation) and no other safety concerns are identified by the DRC, the next dose cohort will be initiated.
[0194] Cohort Dose Deescalation The need for cohort dose de-escalation will be determined by the DRC based on safety assessment for individual subjects and the occurrence of TEAEs leading to dose reduction / discontinuation (see below). If at any time and after 3 subjects in a cohort have been treated, ≥ 30% of subjects in a cohort meet the dose reduction / discontinuation criteria, enrollment into that cohort and / or any higher dose cohorts (if applicable) will be paused and a DRC will be convened. The DRC will determine whether the dose of the current or higher cohort should be de-escalated (i.e., subjects in the current cohort will continue to receive treatment at the next lower dose for efficacy assessment) or whether treatment can continue at the same dose and / or whether cohort expansion is necessary to continue evaluating the safety of that dose level.
[0195] Dose reduction / discontinuation for individual subjects The DRC will monitor subject safety, consider the number of subjects meeting dose reduction / discontinuation criteria, and determine whether cohort dose escalation can proceed or whether dose de-escalation is required at the cohort level, while dose modifications in individual subjects will be managed by the investigator. The following are considered AEs requiring dose reduction / discontinuation in an individual subject: 1. Phosphorus level >4.5 mg / dL (or age-adjusted upper normal level for the reporting laboratory) confirmed by repeat value. 2. Calcium level >10.7 mg / dL (or age-adjusted upper normal level for the reporting laboratory) confirmed by repeat value. 3. Grade ≥2 related treatment-emergent AE (as assessed by investigator). 4. Grade 1 or greater corneal toxicity. Subjects experiencing at least one of the AEs listed above should receive a modified dose as described below. ·below: o Phosphorus and / or calcium levels return to normal, or o Grade ≥2 treatment-related AEs are reduced in severity to < Grade 2 o Abnormal ophthalmological findings are resolved Dose for individual subjects will be withheld until Resume administration at the next lower dose level. If the AE resulting in dose withholding does not resolve within 4 weeks with adequate supportive care, the subject may be discontinued.
[0196] Subject Discontinuation / Withdrawal from Study or Study Drug Premature withdrawal from the study or study medication may occur for any of the following reasons: Subject (or parent / LAR) request or withdrawal of consent. - The AE resulting in dose withholding did not resolve within 4 weeks with adequate supportive care. The investigator deems it in the subject's best interest to discontinue the study drug or study (including but not limited to worsening of growth imbalance, development or worsening of tibial bowing, development of infigratinib-related fractures of the bone and growth plate, and deterioration of range of motion of the elbow). Subjects reach or approach final height as defined by Tanner pubertal stage ≥ 4 and growth velocity ≤ 1.5 cm / year (Marshall 1969; Marshall 1970). Subject has height velocity ≤ 1.5 cm / year for at least 6 months. The subject develops a clinically significant condition requiring treatment with medications that may confound the assessment of efficacy or safety or that are prohibited, such as vitamin D analogues, medications that alter the pH of the gastrointestinal tract (including antacids, H2 antagonists (e.g., ranitidine), and proton pump inhibitors (e.g., omeprazole)), or enzyme-inducing antiepileptic drugs (including carbamazepine, phenytoin, phenobarbital, and primidone) (see Section 8.3 [Main Protocol]). Female subjects become pregnant. · Protocol deviations (at the discretion of the sponsor). -Testing completed by the client. Loss to follow-up.
[0197] statistical methods Sample size Dose escalation and de-escalation rules are based on the BOIN design with a target toxicity rate of 25%. Selection of interval boundaries in Table 10 (primary protocol) is based on a maximum toxicity of 15% at subtherapeutic doses and a minimum toxicity of 35% at supratoxic doses. Additionally, if there is a ≥ 95% probability based on observed data that a TEAE rate > 25% would result in dose reduction or discontinuation, the current dose cohort will be excluded from the trial, and if the initial dose level is excluded, the trial may be terminated or a lower dose may be evaluated following DRC recommendations. Dose selection for dose expansion is based on assessment of approximately 10 subjects / cohort. With a true AE incidence of 25%, 10 subjects / cohort allows for 94.4% confidence in observing at least one AE. Also, with 10 subjects / cohort, there is a 62.5% chance of obtaining a 95% confidence interval (CI) for height velocity at half-width of at most 1.5 cm / year, assuming that the change from baseline in height velocity is normally distributed with a standard deviation of 2 cm / year. In dose expansion, approximately 20 subjects will be enrolled at the selected dose level. An annual height velocity gain of ≦0.5 cm / year is not considered clinically relevant and will be used as the null hypothesis. Assuming a 2 cm / year increase in height velocity with a standard deviation of 2 cm / year after the initiation of infigratinib treatment, 20 subjects will provide approximately 88.9% power to demonstrate that treatment with infigratinib can increase height velocity by >0.5 cm / year at a one-sided significance level of 0.025.
[0198] Dose escalation For dose escalation, all analyses will be performed separately for each treatment cohort based on the initial dose taken and total. Continued analyses will be performed to support the DRC review. The selection of doses to explore in dose expansion will be based on a thorough review of safety and efficacy data after all subjects have had the opportunity to complete 6 months of infigratinib treatment.
[0199] Dose expansion Subjects enrolled in the dose expansion will be analyzed for both safety and efficacy. These data will be used to infer changes from baseline in height velocity. Continued analyses may be performed, as well as a final analysis of the dose expansion, once all subjects are expected to complete 12 months of treatment at the dose expansion.
[0200] statistical analysis All safety analyses will be performed using the safety analysis set, defined as subjects who received at least one dose of study medication. Analyses for growth parameter endpoints will be performed on subjects who had a baseline and at least one post-baseline growth parameter assessment. Baseline and demographic variables will be summarized. Safety summaries will present AEs recorded over the last dose date + 30 days. All TEAEs will be summarized and listed. TEAEs resulting in dose reductions or discontinuations will be summarized. Changes to laboratory measures, disease-specific complications, and surgical procedures will be summarized. For subjects enrolled in dose escalation, baseline and post-baseline weight, height, head circumference, and body proportions, as well as change from baseline in annualized height velocity and change in these parameters will be summarized based on the first 6-month assessment. Assessments conducted after 6 months will provide summaries at 6-month intervals by the dose originally taken. For subjects enrolled in dose expansion, change from baseline in annual height velocity will be examined using a one-sample t-test to assess whether the increase was >0.5 cm / year. Descriptive statistics with 95% confidence intervals will also be provided for height velocity parameters and change from baseline in these parameters, in addition to weight, height, head circumference, and body proportions at baseline and post-baseline. Descriptive statistics will also be provided to explore associations between biomarkers and height velocity. Assessment of disease-specific comorbidities will be summarized by visit.
[0201] Incorporation by Reference This application refers to various issued patents, published patent applications, journal articles and other publications, all of which are incorporated herein by reference. In the event that any of the incorporated references conflict with this specification, this specification shall control. Furthermore, certain embodiments of the present disclosure that fall within the scope of the prior art may be expressly excluded from any one or more of the claims. Such embodiments may be excluded even if the exclusion is not expressly stated herein, since they are deemed to be known to those skilled in the art. Any particular embodiment of the present disclosure may be excluded from any claim for any reason, whether related to the existence of prior art or not.
[0202] Equivalent The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The foregoing embodiments should therefore be considered in all respects as illustrative and not limiting of the invention described herein. The scope of the present invention is therefore indicated by the appended claims rather than the foregoing description, and all changes having the meaning and scope equivalent to the claims are intended to be embraced therein.
Claims
1. A pharmaceutical composition for use in the daily oral administration of about 0.01 mg / kg to about 0.51 mg / kg of infigratinib or a pharma- ceutical acceptable salt thereof to a pediatric patient in need thereof, the pharmaceutical composition comprising infigratinib or a pharma- ceutical acceptable salt thereof for the treatment of achondroplasia or hypochondroplasia.
2. 10. The pharmaceutical composition of claim 1 for administering about 0.01 mg / kg to about 0.3 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof.
3. 10. The pharmaceutical composition of claim 1 for administering about 0.01 mg / kg to about 0.15 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof.
4. 2. The pharmaceutical composition of claim 1 for administering from about 0.015 mg / kg to about 0.13 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof.
5. 2. The pharmaceutical composition of claim 1 for administering about 0.016 mg / kg, about 0.032 mg / kg, about 0.064 mg / kg, about 0.128 mg / kg, about 0.256 mg / kg or about 0.51 mg / kg of infigratinib or a pharma- ceutically acceptable salt thereof.
6. A pharmaceutical composition for treating achondroplasia or hypochondroplasia, comprising infigratinib or a pharma- ceutical acceptable salt thereof, for orally administering from about 0.1 mg to about 8 mg of infigratinib or a pharma- ceutical acceptable salt thereof daily to a pediatric patient suffering from achondroplasia or hypochondroplasia.
7. 7. The pharmaceutical composition of claim 6, comprising about 1 mg to about 7 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
8. The pharmaceutical composition according to any one of claims 1 to 7, for use in a pediatric patient having an FGFR3 mutation.
9. The pharmaceutical composition according to claim 8, wherein the FGFR3 mutation is a G380R mutation.
10. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein infigratinib or a pharma- ceutically acceptable salt thereof is administered as mini-tablets each having 0.1 mg or about 1 mg of infigratinib or a pharma- ceutically acceptable salt thereof.
11. The pharmaceutical composition of claim 10, wherein infigratinib is present in the mini-tablets as infigratinib monophosphate.
12. 12. The pharmaceutical composition of any one of claims 1 to 11, used to demonstrate an increase in height growth rate over baseline in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof.
13. 12. The pharmaceutical composition of any one of claims 1 to 11, used to demonstrate an increase in absolute height velocity in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof.
14. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof is used to demonstrate an increase over baseline in anthropometric measurements selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof in pediatric patients.
15. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof is used to demonstrate in pediatric patients an absolute increase in anthropometric measurements selected from the group consisting of standing height, sitting height, upper and lower arm length, thigh length, knee height, arm span, and combinations thereof.
16. 12. The pharmaceutical composition of any one of claims 1 to 11, used to treat pediatric patients exhibiting weight loss relative to baseline upon daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof.
17. 12. The pharmaceutical composition according to any one of claims 1 to 11, which is used to induce an absolute reduction in body weight in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof.
18. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein a pediatric patient demonstrates a proportional increase in head circumference relative to baseline upon daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof.
19. 12. A pharmaceutical composition according to any one of claims 1 to 11, used to demonstrate an absolute proportional increase in head circumference in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof.
20. A pharmaceutical composition according to any one of claims 1 to 11, used to demonstrate normalisation of body mass index measurements in pediatric patients relative to baseline by daily administration of a dose of infigratinib or a pharmacologic salt thereof.
21. A pharmaceutical composition according to any one of claims 1 to 11, used to demonstrate absolute normalisation of body ratio measurements in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof.
22. 22. The pharmaceutical composition of claim 20 or 21, wherein the body ratio measurement ratio is selected from the group consisting of upper body to lower body body part ratio, upper arm to forearm ratio, upper leg to lower leg length ratio, arm span to standing height ratio, head circumference to standing height ratio, and combinations thereof.
23. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein a pediatric patient is administered a daily dose of infigratinib or a pharma- ceutically acceptable salt thereof to demonstrate an increase over baseline in a biomarker of bone metabolism selected from the group consisting of type X collagen degradation fragments, collagen X markers, and combinations thereof.
24. The pharmaceutical composition of any one of claims 1 to 11, wherein a pediatric patient is administered a daily dose of infigratinib or a pharma- ceutical acceptable salt thereof to demonstrate increased exercise capacity compared to baseline.
25. 12. The pharmaceutical composition of any one of claims 1 to 11, used to demonstrate a reduction in the number of episodes of otitis media versus baseline in pediatric patients by daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof.
26. A pharmaceutical composition according to any one of claims 1 to 11, used to treat pediatric patients showing a reduction in the number and / or severity of sleep apnea episodes compared to baseline with daily administration of a dose of infigratinib or a pharma- ceutical acceptable salt thereof.
27. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein daily administration of a dose of infigratinib or a pharma- ceutically acceptable salt thereof is used to demonstrate an increase in quality of life in pediatric patients, where quality of life is assessed using the Pediatric Quality of Life Inventory.
28. 28. The pharmaceutical composition of any one of claims 1 to 27, wherein the pediatric patient is 12 years of age or younger.
29. 29. A pharmaceutical composition according to any one of claims 1 to 28, for use in a pediatric patient aged between 3 and 11 years.
30. 29. The pharmaceutical composition of any one of claims 1 to 28, wherein the pediatric patient is under 8 years of age.
31. 28. The pharmaceutical composition of any one of claims 1 to 27, wherein the pediatric patient is 8 years of age or older.
32. A mini-tablet for oral administration of 1 mg of infigratinib, A mini-tablet comprising infigratinib monophosphate in an amount to administer 1 mg of infigratinib and pharma- ceutically acceptable excipients.
33. A mini-tablet for oral administration of 0.1 mg of infigratinib, Infigratinib monophosphate in an amount to administer 0.1 mg of infigratinib; and Mini-tablets containing pharma- ceutically acceptable excipients.
34. 34. The mini-tablet of claim 32 or 33, wherein the pharma- ceutically acceptable excipient is selected from the group consisting of mannitol, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium stearate, croscarmellose sodium, and combinations thereof.
35. A mini-tablet for oral administration, comprising: about 1% w / w to about 20% w / w of infigratinib monophosphate, and Minitablets containing from about 30% w / w to about 95% w / w of filler.
36. 36. The mini-tablet of claim 35, wherein the filler is selected from the group consisting of microcrystalline cellulose, lactose, mannitol and combinations thereof.
37. 37. Minitablets according to claim 35 or 36, wherein the filler consists of microcrystalline cellulose and mannitol.
38. 38. The mini-tablet of any one of claims 35 to 37, further comprising about 5% w / w to about 10% w / w of a binder.
39. 39. The mini-tablet of claim 38, wherein the binder is selected from the group consisting of sugar, gelatin, natural gums, sorbitol, maltodextrin, alginate, alginate derivatives, polyvinylpyrrolidone, cellulose, cellulose derivatives and combinations thereof.
40. 40. The mini-tablet of any one of claims 35 to 39, further comprising about 5% w / w to about 10% w / w of a disintegrant.
41. 39. The mini-tablet of claim 38, wherein the disintegrant is selected from the group consisting of starch, starch derivatives, clay, cross-linked cellulose, cross-linked cellulose derivatives, cross-linked polyvinylpyrrolidone and combinations thereof.
